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Background: Crohn´s disease (CD) is a chronic inflammatory disease that can 
affect any part of the digestive tract, including the mouth. The reported prevalence 
of oral manifestations in Crohn´s disease varies widely and ranges from 0.5% to 
80%. Oral manifestations may coincide with the intestinal symptoms or they can 
precede them.  
 
Orofacial granulomatosis (OFG) is a rare chronic inflammation presenting in the 
oral cavity and around the mouth without intestinal involvement. Histology shows 
non-caseating granulomas. Melkersson-Rosenthal syndrome (MRS) is considered 
to be one manifestation of OFG, where granulomatous inflammation and oedema 
is accompanied by recurrent facial palsy and fissured tongue. Oral lesions in CD, 
OFG, and MRS cannot be clinically or histologically distinguished.  
 
Patients with OFG may develop a symptomatic gut disease and it is debated 
whether OFG is an oral manifestation of CD, or a separate inflammatory disorder. 
In addition, it is unknown whether patients with MRS are prone to develop CD in 
follow-up. 
 
The etiology of OFG is unknown. Various etiological mechanisms have been 
suggested. Human leucocyte antigen (HLA) genes affect inflammatory and 
immune responses and certain HLA types are associated with distinct 
inflammatory, infectious and autoimmune conditions. HLAs are also involved in 
the pathogenesis of CD. The role of HLA in OFG is not well-established.  
 
Methods: First, patients with pediatric-onset OFG were examined. A cohort of 29 
patients with pediatric-onset OFG were described in detail, including 
otorhinolaryngological and dental examinations, nutrition from food records, and 
laboratory tests. Orofacial findings were photographed and recorded using a 
structural schema. The findings were compared between patients with OFG only 
and OFG with CD. Possible factors predicting bowel disease in orofacial patients 
were of special interest.  
 
Next, a case-control study was performed on 24 patients with pediatric-onset CD 
who had reached adulthood and 22 matched healthy controls. The presense of oral 
and otorhinolaryngological manifestations in patients with pediatric-onset CD in 
adulthood were investigated. Orofacial findings were evaluated and recorded as 
described in the first study. Questionnaires were used to evaluate patients´ general 
health and health-related quality of life (HRQoL). Nutrition was evaluated from 
food records.  
 
Last, a phone-interview was performed with 27 patients suffering triad or 




(CG). The health outcomes of these patients in long-term follow-up with a special 
emphasis on intestinal symptoms, were of interest. The aim was to evaluate the 
relationship between OFG, MRS, and CD.  
 
Blood samples were collected from patients with OFG, patients with CD and 
controls to investigate inflammatory markers, haemoglobin, and anti-
Saccharomyces cerevisiae antibodies A (ASCAbA) and G (ASCAbG). In patients 
with OFG, the HLA-haplotypes were also examined. HLA-haplotypes of patients 
with OFG were constructed computationally and the results were compared to 
control cohorts of pediatric patients with CD and general population.  
Stool samples were collected from all patient groups to evaluate faecal calprotectin, 
a surrogate marker for intestinal inflammation.  
 
Results: Of the 29 patients with pediatric-onset OFG, 21 (72%) developed CD 
during the time between diagnosis and this study (median 3.1 years). ASCAbA 
levels were higher in patients who developed a symptomatic gut disease compared 
to those with OFG only. Patients with elevated ASCAbA also had more oral findings 
compared to patients with normal levels of ASCAbA (p=0.0311). In addition to 
faecal calprotectin, ASCAbA may serve as a factor predicting underlying or 
developing CD in patients with OFG, but further studies are needed.  
 
Of the 27 patients with MRS or CG, only one (3.7%) CG patient developed CD 
during follow-up of a median 30 years. However, two MRS patients developed 
ulcerative colitis, and thus in total 11.1% had a diagnosis of inflammatory bowel 
disease.   
 
The patients with OFG only and OFG with CD did not differ significantly in the 
HLA-allele or HLA-haplotype frequency. However, HLA-B*44 was more common 
in patients with OFG with CD than in the control group of patients with pediatric 
CD. Compared to the general population, the frequency of HLA-B*44 was twice as 
high in patients with OFG and CD, but the difference was statistically not 
significant. None of the other HLA-alleles or haplotypes linked with OFG. 
 
At the time of the study, almost all patients with OFG had oral lesions, but were 
mostly only slightly symptomatic. Oral mucosa was the most common site for 
orofacial findings, affecting 90% of patients with OFG. In patients with pediatric-
onset CD, oral lesions did not seem to increase during the course of the gut disease 
and they seemed to be inactive when the gut disease was under good therapeutic 
control. Interestingly, oral lesions were more likely to be seen in patients with CD 
with a history of perianal abscesses. Over half of the patients with MRS or CG 
reported oral manifestations at some point during the disease course. Angular 
cheilitis was common in all patient groups.  
 
None of the nutritional factors and none of the dental findings correlated to oral 





Otorhinolaryngological findings were minor in both patients with pediatric OFG 
and patients with pediatric-onset CD in adulthood.  
 
Conclusion: Prognosis for OFG is good. Symptoms tend to diminish during the 
course of the disease and no severe disease exacerbations were seen. In patients 
with CD the oral symptoms seem to be inactive when the gut disease is under good 
therapeutic control. Pediatric CD confers only a modest risk of oral lesions at adult 
age.   
 
OFG and CD do not seem to increase otorhinolaryngological comorbidity.  
 
One possible factor was found that was associated with gut disease in patients with 
OFG. Elevated ASCAbA may serve as a factor predicting the underlying or 
developing CD in patients with OFG. On the other hand, patients with CD and a 
history of perianal abscessing disease seem to be prone to oral manifestations of 
CD. 
 
MRS has a recurrent and chronic disease course. Oral findings are relatively 
common in patients with MRS. This study´s findings suggest a link between MRS 






SUMMARY IN FINNISH 
Crohnin tauti on krooninen tulehduksellinen suolistosairaus, jonka esiintyvyys 
kasvaa nopeasti länsimaissa. Crohnin tauti voi esiintyä missä tahansa 
ruoansulatuskanavan osassa, myös suussa. Crohnin taudin suumuutokset 
kuvattiin ensimmäisen kerran vuonna 1969, mutta suumuutosten käyttäytymistä 
ja yleisyyttä taudin eri vaiheissa ei edelleen täysin tunneta.  
 
Orofasiaalisella granulomatoosilla tarkoitetaan kasvojen ja suun alueelle 
rajoittunutta pitkäaikaista tulehduksellista tilaa, jolle tyypillistä on kasvojen ja 
huulien turvotus sekä suun limakalvojen haavaumat. Orofasiaalisen 
granulomatoosin etiologiaa ei täysin tunneta. Ratkaisua on etsitty viivästyneestä 
allergisesta reaktiosta, infektioista, immunologiasta ja perintotekijöistä. 
Todennäköisesti etiologia on monitekijäinen.  
 
Orofasiaalista granulomatoosia ja Crohnin taudin suumuutoksia ei voida erottaa 
toisistaan kliinisesti tai histologisesti. Muutosten histologia osoittaa 
nonkaseoottista granulomatoottista tulehdusta. Histologialtaan vastaavia 
suumuutoksia voi esiintyä myös sarkoidoosissa ja tuberkuloosissa. Orofasiaalisen 
granulomatoosin taustalla voikin piillä systeemisairaus, kuten Crohnin tauti tai 
sarkoidoosi, mutta usein tila tulkitaan idiopaattiseksi oireyhtymäksi. Osalle 
orofasiaalista granulomatoosia sairastavista kehittyy oireinen Crohnin tauti. 
Melkersson-Rosenthalin oireyhtymässä orofasiaaliseen turvotukseen ja 
granulomatoottiseen tulehdukseen liittyy perifeerinen kasvohalvaus ja uurrekieli. 
Melkersson-Rosenthalin oireyhtymää on pidetty yhtenä orofasiaalisen 
granulomatoosin alamuotona. Sitä, liittyykö Melkersson-Rosenthalin 
oireyhtymään riski sairastua Crohnin tautiin pitkäaikaisseurannassa, ei tiedetä.  
 
Tässä väitöskirjatyössä tutkittiin orofasiaalisen granulomatoosin, Melkersson-
Rosenthalin oireyhtymän ja Crohnin taudin yhteyttä. Lähestyimme kasvo- ja 
suuoireita eri näkökulmista. Ensin tutkittiin orofasiaalista granulomatoosia 
sairastavat potilaat ja etsittiin tekijöitä, jotka voisivat liittyä suolistosairauden 
kehittymiseen suuoireisilla potilailla. Seuraavaksi selvitettiin lapsuudessa Crohnin 
tautiin sairastuneiden jo aikuisiksi varttuneiden potilaiden suuoireita. Crohnin 
tautia sairastavien potilaiden tuloksia verrattiin terveisiin verrokkeihin, jotka 
poimittiin Väestörekisteristä. Viimeisenä selvitettiin Melkersson-Rosenthalin 
oireyhtymää ja sen yksioireista ja yleisempää alamuotoa, cheilitis granulomatosaa 
sairastavien potilaiden oireilua pitkäaikaisseurannassa.  
 
Orofasiaalista granulomatoosia sairastavien potilaiden suuoireilu ei tutkimuksessa 
lisääntynyt taudin edetessä. Jopa 72%:lla potilaista todettiin Crohnin tauti ja 
hieman yllättäen näillä potilailla oli myös enemmän suulöydöksiä verrattuna 
niihin potilaisiin, joilla oli vain orofasiaalinen granulomatoosi. Koholla olevat IgA-




Crohnin tautiin ja runsaampiin suulöydöksiin verrattuna potilaisiin, joilla ASCAbA 
ei ollut koholla. Tutkimuksen perusteella ASCAbA voisi olla tekijä, joka osoittaa 
piilevää tai kehittyvää suolistosairautta suuoireisilla potilailla, mutta 
jatkotutkimuksia tämän osalta tarvitaan.  
 
HLA-alleelin tai HLA-haplotyyppien osalta potilaat, joilla oli orofasiaalinen 
granulomatoosi ja potilaat, joilla oli orofasiaalinen granulomatoosi ja Crohnin 
tauti, eivät eronneet toisistaan tilastollisesti merkitsevästi. HLA-B*44 oli yleisempi 
niillä potilailla, joilla oli orofasiaalinen granulomatoosi ja Crohnin tauti, kuin niillä 
potilailla, joilla oli vain Crohnin tauti. Mikään muu HLA-alleeli tai -haplotyyppi ei 
ollut yhteydessä orofasiaaliseen granulomatoosiin. HLA-B*44 voisi viitata 
lisääntyneeseen OFG:n riskiin, mutta jatkotutkimuksia tarvitaan. 
 
Crohnin tautia lapsuudesta sairastaneiden potilaiden suulöydökset olivat 
tutkimuksessa vähäisiä. Suuoireilu ei näytä lisääntyvän suolistosairauden edetessä 
ja on vähäistä silloin, kun suolistosairaus on hyvässä hoitotasapainossa. Crohnin 
taudin perianaalinen abskessoiva tautimuoto oli yhteydessä lisääntyneisiin 
suuoireisiin, mutta muita selviä suuoireisiin liittyviä tekijöitä ei todettu.  
 
Orofasiaalista granulomatoosia tai Crohnin tautia sairastavien potilaiden 
otorinolaryngologisessa tutkimuksessa ei tullut esille poikkeavaa. Näihin tauteihin 
ei näytä liittyvän lisääntynyttä sairastavuutta korva-, nenä- ja kurkkutautien 
osalta.  
 
Crohnin tautiin tiedetään liittyvän lisääntynyt riski hampaiston ongelmille. 
Tutkimuksessa mikään hammaslöydös ei ollut yhteydessä suumuutosten 
esiintymiseen potilailla, joilla oli orofasiaalinen granulomatoosi tai Crohnin tauti. 
Ientulehdus oli potilailla hyvin yleistä.  
 
Potilaiden ravitsemuksen tutkiminen ei tuonut esille selvää suumuutoksiin 
yhteydessä olevaa tekijää.  
 
Melkersson-Rosenthalin oireyhtymää tai cheilitis granulomatosaa sairastavien 
potilaiden haastattelututkimuksessa ilmeni, että yli puolella potilaista oli ollut 
jossain taudin vaiheessa suuoireita. Vain yksi cheilitis granulomatosaa sairastava 
potilas sairastui Crohnin tautiin 30 vuoden (mediaani) seurannan aikana. 
Kuitenkin kahdella Melkersson-Rosenthalin oireyhtymää sairastavalla potilaalla 
todettiin haavainen paksusuolitulehdus seuranta-aikana, joten yhteys 
Melkersson-Rosenthalin oireyhtymän ja tulehduksellisten suolistosairauksien 





Crohn´s disease (CD) is a chronic inflammatory disease of the gastrointestinal 
tract with increasing incidence worldwide. The incidence of CD is highest in 
Europe and North America, ranging from 10 to 30 cases per 100 000 person-years 
[1]. The incidence of CD in Finland is 9.2 cases per 100 000 inhabitants per year 
[2].   
 
Terminal ileum and colon are the most common segments of the gastrointestinal 
tract affected in CD but it can also manifest in the oral cavity. The oral 
manifestations in CD were first described in 1969 [3]. It has been estimated that 
0.5 – 50% of patients with CD have oral manifestations and in children with CD 
the prevalence is even higher.  
 
Granulomatous inflammation manifesting with facial oedema and facial palsy was 
first described by Melkersson in 1928 [4]. In 1931, Rosenthal presented a patient 
with orofacial swelling, facial palsy and lingua plicata, and suggested a connection 
between these findings [5]. Since 1949, the triad has been known as Melkersson-
Rosenthal syndrome (MRS) [6]. Orofacial granulomatosis (OFG) was first 
introduced in 1985 to describe orofacial swelling and granulomatous inflammation 
without evidence of systemic disease [7]. The term “OFG” encompasses the 
previously described entities with granulomatous inflammation in the orofacial 
area without any underlying systemic condition. However, the connection between 
OFG and MRS is not completely clear, and there is conciderable overlap in the 
classification.  
 
It is known to date that patients with OFG can develop a symptomatic gut disease 
and patients with CD may have oral manifestations. It is debated whether OFG is 
an oral manifestation of CD, or a distinct inflammatory entity. The possibility of a 
third entity, namely OFG with gastrointestinal involvement, has been proposed 
recently. Clinicians are particularly interested in understanding the factors that 
predict underlying or future gut disease in patients with OFG. In addition, the 
relationship between MRS and CD is not well established.  
 
Orofacial lesions in both CD and OFG can cause notable discomfort and concern 
in patients. Due to a growing incidence of IBD, the number of people who suffer 
from orofacial lesions is growing. These patients are encountered by physicians in 
many specialities. Pediatricians, dentists, gastroenterologists, and 
otorhinolaryngologists, as well as general practitioners, should be aware of this still 
rare entity. Gaining more knowledge of this disease spectrum is the key for better 
understanding and helping patients. 





2 REVIEW OF THE LITERATURE 
2.1 CROHN´S DISEASE  
Ulcerative colitis (UC) and Crohn´s disease (CD) are chronic inflammatory bowel 
diseases (IBD). For both diseases, autoimmune type inflammation is typical. UC is 
restricted to the mucosa of colon, whereas CD can affect any part of the digestive 
tract. Disturbances in immune responses and altered intestinal microbiota play 
important roles in the pathology of IBD [8]. A genetic predisposition is also 
evident, although significant predisposing factors are yet unknown [9]. The 
incidence of IBDs is growing rapidly in Western countries [1,10]. In Finland, UC is 
still more common than CD, but in the rest of Europe, CD is notably more common 
[11-13]. The onset of CD typically occurs in the second to fourth decade of life, but 
the disease can occur also in childhood. About 25% of the cases are diagnosed 
during childhood [8].  
 
CD typically affects the terminal ileum and colon but has potential to affect any 
part of the gastrointestinal tract including the oral cavity [14]. Oral manifestations 
in CD were first described in 1969, but it remains uncertain regarding how 
frequently these manifestations occur among patients with CD [15] and how they 
act during different stages of gut disease. Oral manifestations may coincide with 
the intestinal symptoms of CD or precede them.  
 
Oral manifestations in CD are typically divided into disease-specific and non-
specific lesions. Specific lesions result from the same disease process as CD in the 
gut, namely granulomas that can be identified by histology. These specific lesions 
include swelling of the lips, cheeks and gingiva, cobblestone formation of the 
mucosa, deep linear ulcers, and mucosal tags [16-18]. Lesions may be preceded by 
painless gingival enlargement [19]. Non-specific lesions are reactive lesions 
without granulomas [18]. Patients with CD often suffer from aphthous ulceration, 
angular cheilitis, lip fissuring, and gingivitis, but these are not specific to CD [18]. 
The most common lesion that has been reported is cobblestoning, which is 
described by fissured swollen buccal mucosa with corrugation and hyperplasia of 
the mucosa, followed by linear ulcers [20]. The lips [21] and labial commissure 
[22] have been reported to be the most frequently affected sites. In reviews on 
pediatric patients, mucogingivitis [17] and oral ulceration [18] have been reported 
to be the most common oral lesions. 
 
In the published literature, the reported prevalence of oral manifestation in 
patients with CD has varied widely, ranging between 0.5% and 50% in adult 
cohorts [17,23,24] and between 10% and 80% in pediatric cohorts [18]. The wide 




and ethnic groups, experience of the examiner, definition of disease-specific 
lesions and whether the patient is on treatment for CD at the time or not [17].  
 
2.2 OROFACIAL GRANULOMATOSIS 
Orofacial granulomatosis (OFG) is an uncommon chronic condition described by 
granulomatous inflammation restricted to the orofacial area. The term was first 
described in 1985 as an idiopathic entity of orofacial swelling and granulomatous 
inflammation without evidence of systemic disease [25]. Primary symptoms are 
oedema in the lips and face, and ulceration in the mouth [25]. Histology shows 
noncaseating granulomas. Oral lesions identical to OFG can be seen in CD, 
tuberculosis, and sarcoidosis. OFG can be accompanied by a systemic disease like 
CD or sarcoidosis, but usually it is referred as an idiopathic entity of its own [26]. 
In Melkersson-Rosenthal syndrome (MRS), orofacial oedema and granulomatous 
inflammation are accompanied by facial palsy and fissured tongue (lingua plicata) 
[6,27]. Cheilitis granulomatosa (CG) is considered to be a monosymptomatic form 
of MRS. It comprises chronic facial or labial swelling due to granulomatous 
inflammation. The major findings in OFG, MRS, and CG are described in Table 1.  
 
OFG may be used as an umbrella term to encompass all previously described 
granulomatous entities in the orofacial area [28], including MRS and CG. 
However, there is conciderable overlap in the nomenclature and precise 
classification is not always even possible, especially on initial presentation when 
all clinical features may not be present.   
 
 
Table 1. Typical clinical features in orofacial granulomatosis (OFG), Melkersson-
Rosenthal syndrome (MRS) and cheilitis granulomatosa (CG).  
 
Typical clinical features 
OFG MRS CG 
   
facial oedema recurrent orofacial oedema facial or labial oedema 
labial oedema recurrent facial palsy  










The etiology of OFG remains largely unknown. Etiological factors have been sought 
from various directions. Genetic, immunologic, allergic, and infectious 
mechanisms have been proposed [26,28,29]. Due to various study results the 
etiology seems most likely multifactorial. 
2.2.1.1 Genetic mechanisms 
 
A familial association was suggested after a study of 42 patients with OFG and their 
171 relatives found lingua plicata in 23% of the families [30]. It has since been 
reported that 10% of the normal population can have lingua plicata [31], which 
weakened the assumption of a familial association.   
 
The human leukocyte antigen (HLA) system is a gene complex encoding the major 
histocompatibility complex in humans. HLAs are cell-surface proteins responsible 
for the regulation of the immune system. HLAs are highly polymorphic and have 
multiple different alleles and therefore fine-tune the adaptive immune system. 
Certain HLA types are associated to distinct inflammatory, infectious and 
autoimmune conditions, like type 1 diabetes and celiac disease [32]. HLAs are also 
involved in the pathogenesis of CD. Interest in the possible connection between 
OFG and HLA has risen. Whilst two studies failed to show a strong association 
between HLA and pathogenesis of OFG [33,34], HLA genotypes A3, B7, and DR2 
were associated with OFG in a small study of 16 patients with OFG compared with 
normal population [35]. In another study, HLA-B16 and HLA-CW3 were more 
common in patients with MRS compared to normal population, but the difference 
was not statistically significant [33]. Results with small study cohorts show that 
OFG might link to specific HLA genotypes and haplotypes, but further studies are 
needed. 
2.2.1.2 Allergic mechanisms 
 
Delayed-type hypersensitivity reaction, particularly contact hypersensitivity, to 
various food substances and food additives has been proposed as etiology of OFG 
[26,36-38]. Wheat, dairy products, chocolate, eggs, peanuts, cinnamaldehyde, 
piperitone, cocoa, carvone, carmoisine, sun yellow dye, monosodium glutamate, 
and benzoic acid, for example, have been reported as causative or contributing 
agents to OFG [26,28]. Up to 60% of the patients with OFG are atopic, which 
supports the theory of an allergic background [39-41]. Allergy to tooth-paste and 
dental materials, such as mercury and amalgam, has also been described in case 
reports [42-44]. A study evaluating the utility of cutaneous patch testing showed 




especially benzoic acid and chocolate, than other disease cohorts or controls [45]. 
No reactions to cutaneus patch tests for mercury or other metallic salts, indicating 
reactions to amalgam, were observed in patients with OFG [45].  
 
Delayed-type hypersensitivity reaction appears to play a significant role according 
to case reports, although the exact antigen inducing the immunological reaction 
seems to vary in individual patients [26]. Avoidance of causative substances may 
help some patients to manage the symptoms of OFG [39,46,47], but it is unknown 
whether these substances are the primary causative agents or exacerbate the 
existing disease.  
2.2.1.3 Infectious mechanisms 
 
The involvement of microbiological agents in the etiology of OFG has been 
suggested, but the definite role of infections remains unclear. Studies focus mainly 
on Mycobacterium tuberculosis, Mycobacterium paratuberculosis, Saccharomyces 
cerevisiae and various types of spirochetes [26]. Studies investigating the role of 
mycobacteria in the etiology of OFG have comprised small patient groups, and 
shown controversial results, thus the relationship between mycobacteria and OFG 
remains unclear [28]. Anti-saccharomyces cerevisiae antibodies (ASCAb) have 
been associated with CD [48], and one study has reported an association to oral 
involvement [48,49]. Assessment of anti-saccharomyces cerevisiae antibodies in 
the serum and saliva of patients with OFG and CD demonstrated that, salivary IgA 
antibodies was higher in patients with oral disease, and serum IgA antibodies were 
raised in the groups with gut disease [50]. This suggests that serum IgA antibodies 
to Saccharomyces cerevisiae may serve as a serological marker for the development 
of gastrointestinal involvement in patients with OFG [50]. The role of Borrelia 
burgdorferi in OFG was investigated in a small study, but Borrelia burgdorferi 
antibodies could not be detected in the serum of the patients [51]. However, in 
patients with CG and MRS, antibodies against Borrelia burgdorferi were found in 
up to 82% of the patients [52]. The role of spirochetes remains unclear, although 
Chinese studies have demonstrated the presence of spirochetes in Chinese patients 
with CG or MRS [52-54]. 
2.2.1.4 Immunologic mechanisms 
 
OFG is characterized by non-caseating epithelioid granulomas. Additional features 
include significant lymphoedema and both diffuse and focal aggregates of 
lymphocytes, mostly CD4+ T cells [25]. One study compared the T-cell surface 
receptors present on lymphocytes at the site of the lesion to those of peripheral 
blood lymphocytes and found no significant difference [55]. This indicates that the 




random influx of inflammatory cells [55]. The idea of random influx of T-cells at 
the site of inflammation was supported in a later study [56]. Clonal expansion of 
peripheral T cells has also been reported [57]. Elevation of IL-2 in peripheral blood 
lymphocytes has been also reported, which suggests that circulatory lymphocytes 
are activated in OFG [58]. A significant increase of IFN-γ expression in oral lesions 
of OFG together with increased levels of IL-12 suggest a Th1-mediated immune 
response in patients with OFG [59]. Increased levels of certain chemokines and 
chemokine receptors also indicate Th1-mediated immune response with strong 
resemblance with the inflammatory reaction present in gut lesions of patients with 
CD [59]. In addition, subepithelial dendritic B-cells have also been found in 
biopsies from patients with OFG [60]. 
2.2.2  EPIDEMIOLOGY 
 
The precise prevalence and incidence of OFG is not known. OFG appears to be 
most prevalent in young adults, although it may occur at any age [28]. OFG seems 
to affect both sexes equally and is not restricted to any racial group [28]. 
Nonetheless, it has been suggested that OFG is more prevalent among “Celtic” 
populations [61]. A recent study from Sweden suggests that there might be 
geographical differences in the epidemiology of OFG [62]. In the Swedish cohort, 
there was a clear predominance of males (female/male ratio 1:2.6), whereas the 
patients in the UK and Ireland have showed a more equal gender distribution [62-
64]. In the Swedish cohort, the patients were also younger with a median age of 14 
years (range 7-32) compared to those reported from the UK (median 23 years) and 
Ireland (median 28 years) [62-64]. 
2.2.3 CLINICAL FEATURES 
 
OFG classically presents with non-tender recurrent labial oedema that may 
become persistent after recurrences [25]. More recently, it has been understood 
that OFG has a very variable presentation. It may affect only the lips, which is the 
most common site, or all facial tissues. Typical is painless and nonpruritic oedema 
that may be mild and recurrent, but may progress to more severe, persistant 
oedema causing cosmetic and functional problems. The oedema may be 
asymmetric, involving one or both lips or only one side of the lip. The swollen lip 
may feel soft, firm or nodular on palpation, and when the swelling has become 
chronical, rubbery firm. Labial oedema can be accompanied by lip scaling and 
vertical fissures of the lips. Oedema can also manifest in other facial tissues. Oral 
manifestations include angular cheilitis, mucosal ulceration, mucosal tags, 
swelling of the mucosa, and fissured dorsum of the tongue (lingua plicata) [25]. 
Generalized swelling of the buccal mucosa leads to a cobblestone-like appearance. 




mucosa, or in the floor of the mouth where the finding is described as staghorning. 
Deep chronic linear ulcers in the buccal or labial sulcus can cause significant pain 
[65]. Gingivitis and gingival overgrowth is also reported. 
 
The most common presentation of OFG is lip swelling and facial swelling, which 
are reported in more than 90% of the cases [64,66]. Labial swelling was the most 




Characteristic histopathological features include non-caseating, i.e. non-
necrotising, granulomas with multinucleate giant cells, dilated lymphatics, and a 
perivascular lymphocytic infiltrate [7,29,59]. However, nonspecific infiltration of 
inflammatory cells may be the only histopathological finding in biopsies, as 
granulomas are not always present [6,68].  OFG and oral lesions in CD cannot be 
histologically distinguished. A recent study evaluated the histopathology of 22 
patients with OFG and found discrete loose epithelioid cell or lymphonodular 
granulomas as the most specific finding in 73% of the patients. None of the patients 
in this study developed CD, but the authors agreed that OFG is histopathologically 
similar to lesions of CD [69]. The perilymphatic disposition of granulomas and the 
presence of intralymphatic histiocytes or intralymphatic granulomas may explain 
the dilatation of lymphatic vessels and the development of oedema [69]. 
2.2.5 DIAGNOSIS 
 
The diagnosis of OFG is clinical and based on patient´s history and typical clinical 
features. Biopsy of an affected area for hematoxylin and eosin staining may be 
helpful to find histologic evidence of noncaseating granulomas. However, biopsy is 
not mandatory for the diagnosis, and can also be negative for granulomas 
[6,68,70]. To date, additional diagnostic studies are tailored for each individual 
patient and mostly aim to exclude other conditions characterized by granulomas, 
including CD, tuberculosis, and sarcoidosis. Additional diagnostic studies may 
include skin patch or prick testing (to assess allergy), chest radiography (hilar 
adenopathy found in tuberculosis and sarcoidosis), assessment of angiotensin 
converting enzyme (increased in sarcoidosis), levels of hemoglobin, folate, 
iron/ferritin and vitamin B12 (decreased in CD), inflammatory markers (increased 
in CD), tuberculosis testing (tuberculin skin test or interferon γ release assays) and 
if gastrointestinal involvement is suspected, endoscopy including biopsies [28,29]. 
Capsule-endoscopy has its place in investigating the small intestine in case of 




Childhood onset, laboratory abnormalities, and gastrointestinal symptoms are 
features that may indicate a need to evaluate for concurrent or future CD [28]. 
2.2.5.1 Differential diagnosis 
 
Differential diagnosis includes trauma, infection and angioedema, which are the 
most common reasons for labial edema. However, in these conditions labial 
swelling is typically transient. Allergic angioedema may manifest as non-pitting 
oedema of the lips, tongue, pharynx and face. A predispositional factor may be 
identifiable and patients may have a history of atopy, which however is often true 
for patients with OFG as well. Differential diagnosis includes other conditions 
characterized by granuloma formation, including CD, tuberculosis and sarcoidosis. 
In CD orofacial findings are similar to those of OFG, although oro-cutaneous 
fistulas and pyostomatitis vegetans are suggestive of CD [28,29,71]. Tuberculosis 
manifests as localized labial swelling and ulcers, and lesions are often severe [72]. 
In tuberculosis histology usually contains caseating granulomas, whereas in OFG 
the granulomas are non-caseating. Risk factors for tuberculosis include HIV, 
immigration from high-risk regions, alcoholism, intravenous drug use and 
diabetes mellitus. In chronic sarcoidosis, patients may also have pulmonary, 
cutaneous, lacrimal, salivary, neurological and skeletal features of sarcoidosis. 
Granulomatosis with polyangiitis, formerly Wegener´s granulomatosis, can also 
include oral lesions, although other symptoms dominate [73,74]. Cheilitis 
glandularis causes labial enlargement with ulcers and intermittent discharge of 
clear fluid. Histology in cheilitis glandularis shows non-granulomatous 
inflammation in minor salivary glands of the lip [29,71,75]. Other conditions 
causing orofacial symptoms that may resemble OFG include rosacea, acne vulgaris, 
contact dermatitis, exfoliative cheilitis, lichen planus, actinic cheilitis and 
lymphedema [76]. Some lesions seen in OFG, like aphtous ulcers and angular 
cheilitis, are seen also in otherwise healthy individuals.  
2.2.6 TREATMENT 
 
Treatment of OFG is challenging and must be tailored to each individual patient. 
Various options for treatment are reported (Table 2), but a gold standard OFG 
treatment is lacking.  
 
Avoidance of identifiable allergens in food or the environment may help to manage 
the condition [28,39,46,47]. Improvement of OFG symptoms has been reported 
with cinnamon- and benzoate-free diet in 54-78% of patients with OFG, and 23% 
required no other treatments [63]. A low phenolic acid diet with micronutrient 
supplementation has given promising results in the treatment of OFG, but further 
studies of long-term outcomes are needed [77]. Topical treatments, including 




mild disease. Combining topical treatment to parenteral medication increases the 
effect [67]. Systemic and intralesional corticosteroids are the most popular therapy 
for OFG. Intralesional corticosteroids, triamcinolone for example, are felt to be 
safe and effective, and are favoured over systemic corticosteroids due to the well-
known side effects of the latter [28]. Combined therapy with topical and 
intralesional corticosteroids or systemic medications was most effective to control 
the lesions of OFG [67]. Antihistamines provide no help for the symptoms of OFG 
[78]. Oral antibicrobials, including lymecycline, minocycline, roxithromycin, 
metronidazole, and atzithromycin may be effective in some patients [28]. 
Clofazimine and thalidomide have also been reported as effective therapy [28,66]. 
Tumor necrosis factor alpha (TNFα) inhibitors, infliximab and adalimumab, have 
shown promising results in the treatment of OFG, although the majority of patients 
lost responsiveness over the long term [28,79]. A recent study treated 60 OFG 
patients with azathioprine, which was significantly more effective in patients with 
concomitant CD [80]. The group did not recommend azathioprine as the primary 
treatment in patients with OFG alone [80]. Another study treated OFG patients 
with Exclusive Enteral Nutrition (EEN), which is a recognized treatment for 
induction of remission in CD in children [81,82].  A good clinical response to OFG 
symptoms was observed in 19 of the 29 children treated with EEN [82]. EEN may 
be an effective treatment option for children with OFG or OFG with CD [82]. Small 
case series and case reports have also found effective treatment outcomes in 
response to hydroxychloroquine, methotrexate, dapsone, and mycophenolate 
mofetil [28]. Surgery may be considered in disfiguring cases after the disease is 
stabilized with medical therapy.   
 
 
Table 2. Treatments for orofacial granulomatosis reported in the literature. 
 
                        Treatment 
Dietary   Systemic 
Cinnamon- and benzoate free diet Systemic corticosteroids 
Avoidance diet (identifiable allergens) Oral antimicrobials 
Low phenolic acid diet Clofazimine 
Exclusive Enteral Nutrition (EEN) Thalidomide 
Topical Tumor necrosis alpha (TNFα) inhibitors 
Topical corticosteroids      Infliximab 
Topical calcineurin inhibitors      Adalimumab 
Intralesional Azathioprine 
Intralesional corticosteroids Methotrexate 
    Triamcinolone Dapsone 
 Mycophenolate mofetil 






2.2.7 MELKERSSON-ROSENTHAL SYNDROME 
 
Melkersson-Rosenthal syndrome (MRS) is a rare disorder that is often referred to 
as one manifestation of OFG. The classic form of MRS consists of a triad of 
symptoms; recurrent facial palsy, recurrent orofacial or labial oedema, and 
plicated or fissured tongue (lingua plicata) [6]. All three symptoms are present only 
in a minority of patients. The symptoms can also manifest nonsimultaneously, and 
have intervals of months or years between them [6], which makes the diagnosis of 
this condition more challenging. The diagnosis can often only be determined after 
several years of follow-up. A monosymptomatic and more common form of MRS, 
with only orofacial or labial oedema, is called cheilitis granulomatosa (CG). 
Histology in MRS, including CG, shows non-caseating lymphoepithelioid 
granulomas identical to OFG [6,27,83].   
 
The incidence of MRS is undefined [27]. MRS can affect patients of any ages, but 
typically it begins between the second and third decade of life [6,27,68,84,85]. 
Orofacial swelling is the most common manifestation of the disorder, and the most 
important diagnostic feature [6,27,83,84,86]. Oral involvement is common, and 
can include buccal and labial swelling, as well as gingival, palatal, and lingual 
manifestations [6,68]. Swelling of the supraorbital or infraorbital tissues and 
cheeks has been reported [6]. The swelling is usually nonerythematous, painless, 
and nonpruritic, and it typically resolves after the first appearance. After 
recurrences, the swelling may become more persistent and can lead to chronic, 
fissured and reformed swelling. Facial paralysis and fissured tongue are estimated 
to occur in approximately a third of patients [6], and the whole triad in a quarter 
of patients with MRS [87]. Facial palsy is caused by lower motor neuron paralysis. 
The palsy usually has a sudden onset, and is clinically indistinguishable from 
idiopathic Bell´s palsy. Compared to Bell´s palsy, facial palsy in MRS has a higher 
genetic predilection and recurrence tendency [88], as well as a worse prognosis 
[89]. 
 
As for OFG, the etiology of MRS is unknown. Various theories have been proposed, 
including infectious, autoimmune, allergic, and genetic. The relationship between 
MRS and CD has been proposed [90], but remains uncertain [6,17,84,91]. 
 
The diagnosis of MRS is clinical and based on patient´s history and clinical 
features. Neuroimaging examinations may be needed to exclude other diseases, for 
example neurosarcoidosis. Histologic evidence of granulomas confirms the 
diagnosis, but it is not mandatory for the diagnosis. As in OFG, the granulomatous 
changes are not always present in biopsies, and their absence does not exclude the 
diagnosis of MRS.  If taken, the biopsy is advised to take during acute oedema for 





MRS is associated with additional clinical findings, which may help the diagnostics 
in oligo- or monosymptomatic cases. Hyperhidrosis, hypogeusia, acroparesthesia, 
hyperacusis, epiphora, migraine [6], trigeminal neuralgia, keratitis, psychotic 
episodes, uveitis [85], and tinnitus have been reported.  
 
Treatment of MRS is challenging. There is no specific treatment and thus far the 
management is mostly empiric. Systemic corticosteroids are the most common 
current and noninvasive treatment [85]. 
 
2.3 OFG AND CROHN´S DISEASE 
As stated earlier, the term OFG is used to describe patients with granulomatous 
lesions in the orofacial area without evidence of CD or other systemic disease. 
Patients with CD who have oral manifestations are often described as having oral 
CD (OCD). Patients with OFG who have developed CD are referred in the literature 
as OFG with CD. However, there is overlap between the definitions.  
 
Oral manifestations in CD and OFG cannot be distinguished clinically or 
histopathologically. The relationship between these entities is not completely clear. 
Clinicians have debated whether OFG is an oral manifestation of CD, or a chronic 
inflammatory disease of its own. Factors predicting the development of gut disease 
in patients with OFG, and factors associated to oral manifestations in patients with 
CD, are sought in numerous studies.   
 
It has been suggested that onset of OFG in childhood is predictive for the 
development of CD [38,63,92]. In addition, some clinical features are suggested to 
associate more to CD than OFG only. These include ulceration of the mucosa, 
involvement of the buccal sulcus, elevated inflammatory markers, fistulae 
formation, and pyostomatitis vegetans [15,17,63,92]. A study from the UK reported 
distinct clinical oral features in patients with OFG only and OFG with CD, the first 
having more lip involvement and the latter involvement of the buccal sulcus, 
ulcers, and mucosal scarring [63]. In a Swedish cohort of 29 patients, no significant 
difference in the oral phenotype was found between patients with OFG, with or 
without CD [62]. On the other hand, CD with concomitant OFG seems to represent 
a distinctive subtype of CD, that is characterized by extensive inflammation, 
perianal disease, and pronounced granuloma formation in the intestine [93].  
 
Genotypic differences in OFG and CD have been reported. Nucleotide binding 
oligomerization domain containing protein 2 (NOD2) is a gene strongly associated 
with CD [94-96]. In a study of 29 patients, none of the 17 patients with OFG carried 
the NOD2 variant, whereas 4 of the 12 patients with oral CD carried a certain NOD2 
variant [62]. A larger study of 201 patients with OFG found significant enrichment 




only [80].  These findings support that genetic variants in NOD2 seem to be 
associated with OFG in patients with concurrent intestinal disease [62,80].  
 
Anti-saccharomyces cerevisiae antibody A (ASCAbA) is noted as a serological 
marker for CD [97-99]. Assessing ASCAbA in serum and saliva in patients with 
OFG and CD, salivary IgA antibodies was higher in patients with oral disease, and 
serum IgA antibodies higher in patients with gut disease [50]. This suggests that 
serum ASCAbA may serve as a marker of coincident gut disease in patients with 
OFG, and as a screening marker for possible development of CD [50].   
 
Calprotectin is a dimeric calcium-binding protein. It contributes approximately 
60% of the cytosol in neutrophils [100,101]. Inflammatory processes in the gut 
result in accumulation of neutrophils in the intestinal mucosa, and this results in 
the release of calprotectin in the stools, where it can be measured [100,101]. 
Measurement of faecal calprotectin is considered as a reliable marker of intestinal 
inflammation with a good clinical sensitivity in differentiating organic and 
functional conditions [100]. It is not specific for IBD, but it has a high negative 
predictive value in ruling out IBD in undiagnosed, symptomatic patients [102]. In 
patients with diagnosed IBD, faecal calprotectin is used in monitoring, giving 
evidence of either relapse or mucosal healing [102,103]. Measuring faecal 
calprotectin can be useful in identifying underlying gut disease also in patients with 
OFG [104,105]. 
 
It has been suggested that OFG with gastrointestinal tract involvement may be an 
own entity separate from OFG and CD [15,25,28]. This theory was proposed in a 
study, where ileal or colonic abnormalities were found in 19 of 35 (54%) patients 
with OFG and no gastrointestinal symptoms. Only two of these patients had 
endoscopic findings typical for CD [15]. This theory suggests three entities: oral CD 
(gastrointestinal CD with oral involvement), OFG with gastrointestinal 
involvement (OFG with subclinical or asymptomatic gastrointestinal endoscopy 






3 AIMS OF THE STUDIES 
OFG is a rare inflammatory condition affecting the orofacial area. Descriptive 
studies of OFG, its clinical presentation, management and long-term behaviour, 
are limited and typically consist of small number of patients. Precise diagnostics 
concidering the spectrum of OFG, including MRS and CG, is challenging and there 
is conciderable overlap in the classification. CD can cause oral manifestations 
similar to those in OFG, and the relationship between OFG and CD remains 
debated. Patients with orofacial symptoms can present to physicians in many 
specialities. Gaining more knowledge of this disease spectrum is needed for better 
recognition of the patients and to enable developing better treatments for these 
patients in the future.   
 
The aim of this thesis was to investigate and compare conditions presenting with 
orofacial symptoms —OFG, CD, and MRS— and study the connection between 
these entities. 
 
The specific aims of the studies are as follows : 
 
I Evaluate and describe a cohort of pediatric OFG patients in detail, and study 
the long-term outcome of OFG, including dental and otorhinolaryngological 
status, and to evaluate possible factors predicting the development of CD in 
patients with OFG. 
 
II Investigate the association of human leukocyte antigen (HLA) alleles and OFG.   
 
III Examine the oral and otorhinolaryngological lesions and symptoms in patients 
with pediatric-onset CD when they reached adulthood, evaluate the factors 
associated with oral manifestations, study the long-term oral health outcomes 
and the health-related quality of life of patients with CD, and compare the 
findings to healthy controls.   
 
IV Study the long-term health outcomes of patients with MRS having emphasis on 
the oral and intestinal symptoms, and investigate the incidence of CD in 







4 MATERIALS AND METHODS 
4.1 STUDY I AND II 
Patients diagnosed with pediatric OFG and treated between January 2000 and 
March 2014, at Helsinki University Children´s Hospital and department of 
Dentistry, Tampere University Hospital, Finland, were enrolled to this study 
performed between November 2013 and March 2014. The diagnosis of OFG was 
based on typical clinical features assessed by a dentist and a gastroenterologist and 
in most patients also a mucosal biopsy had been obtained showing granulomatous 
inflammation. The diagnosis of CD fulfilled the diagnostic Porto criteria including 
endoscopies with biopsies and small bowel imaging.  
 
Altogether 29 patients (15 patients in Helsinki and 14 patients in Tampere) of the 
total of 40 traced patients agreed to the study. 
 
Study visits (study I) 
 
Patients were clinically examined using a structural schema by an 
otorhinolaryngologist (AH) and a dentist (HA/LA/US). The 
otorhinolaryngological examination (appendix 2) included fiberoscopic 
laryngoscopy. Findings in the face and mouth were recorded with digital 
photographing. Orofacial findings were carefully recorded using Oral disease 
activity score chart for OFG [36] (appendix 1). In the score, each site involved is 
scored individually for activity and type of lesion, with the total score indicating 
global severity, and the maximum total score being 87 [36]. The oral examination 
was carried out in a dental unit using a dental mirror, a dental and periodontal 
probe, fiber optic illumination, and appropriate dental lighting. Radiographs were 
not included in the study. The oral hygiene level was assessed according to the 
Silness-Löe plaque Index [106]. The periodontal condition was assessed by 
measuring the depth of periodontal pockets and the presence of bleeding after 
probing in all teeth. Dental caries were recorded with DMFT (decayed, missing, or 
filled teeth)-index [107]. 
 
Questionnaires (study I) 
 
Patients, or in minors under the age of 18 years their guardians, were asked to 
complete questionnaires about general health, medication, preceeding use of 
antibiotics, bowel-related symptoms, orofacial symptoms, and special diets. To 
assess patients´ subjective opinion of their symptoms, patients were asked to 
evaluate the severity of their orofacial and bowel-related symptoms at the time of 
the study visit on a Likert scale with 7 response points, where 1 represents no 




To evaluate the patients´ nutrition, they were requested to keep a food record for 
3 subsequent days before the scheduled study visit. The use of dietary supplements 
was also queried in the food records. A dietitian recorded the food records with a 
software that is based on a national database of foods. Information about given 
therapies was collected from the patient charts.  
 
Laboratory investigations (study I) 
 
Patients were requested to provide a stool sample for measuring faecal calprotectin 
to evaluate the possible inflammation in the gut. Calprotectin levels were measured 
in a routine clinical laboratory using a quantitative enzyme immunoassay (PhiCal 
Test, Calpro AS, Oslo, Norway), and values of <100 μg/g were considered to be 
normal [108,109]. Blood samples were collected from all patients to measure C-
reactive protein (CRP), erythrocyte sedimentation rate (ESR), hemoglobin, blood 
leukocyte count, and anti-Saccharomyces cerevisiae antibodies A (ASCAbA) and G 
(ASCAbG).  
 
Laboratory investigations (study II) 
 
To investigate the connection between HLA and OFG, the HLA-haplotypes from 
blood samples of the patients were analysed. Genomic DNA was extracted from 
EDTA-anticoagulated whole blood. HLA-haplotypes were constructed 
computationally with PHASE, a software that uses a Bayesian theorem [110]. 
Pediatric patients with CD (n=61) and the general population cohort (n=150) 
served as controls. 
  
 
The Ethics Committee of Helsinki University Hospital approved the study and the 
subjects, or in minors under the age of 18 years their guardians, signed an informed 
consent form.  
4.2 STUDY III 
 
This case-control study was performed between September and December 2016. 
To study the oral manifestations in CD, Finnish-speaking adult patients from the 
Helsinki capital region who were born between 1987 and 1997 and diagnosed with 
CD in childhood after the year 2000 at the Helsinki University Children´s 
Hospital, Finland, were enrolled. As in study I and II, the diagnosis of CD fulfilled 
the diagnostic Porto criteria, including endoscopies with biopsies and small bowel 
imaging. The patients were invited to the study regardless of whether they had a 
history of oral CD or not.  
Healthy controls matched for age and sex were collected from the Population 







Patients and controls were examined as in study I using a structured schema by a 
dentist (HA/LA/US) and an otorhinolaryngologist (AH). The schema of the study 




Questionnaires were used to evaluate subjects´ general health, medication, special 
diets, and lifestyle habits including smoking and alcohol comsumption. Health-
related quality of life (HRQoL) was evaluated using the 15D questionnaire which is 
a generic, standardized, self-administered measure of HRQoL for individuals aged 
16 years or older (appendix 3). The 15D includes the following 15 dimensions: 
breathing, mental function, speech (communication), vision, mobility, usual 
activities, vitality, hearing, eating, excretion, sleeping, distress, discomfort and 
symptoms, sexual activity, and depression. For each dimension there is one 
question, and each question has five possible responses. The 15D can be used as a 
profile instrument, but it can also provide a single index 15D score, ranging from a 
maximum of one when there are no problems on any dimension to the minimum 
of zero when the subject has died [111]. A change of 0.015 in the total 15D score is 
considered to be the minimum clinically important difference that a patient can 
feel [112]. 
 
To evaluate how patients experience their symptoms, the patients were requested 
to evaluate the severity of their gut symptoms and possible orofacial symptoms at 
the time of the examination, on a Likert-scale with 7 response points where 1 
represents no symptoms and 7 very difficult symptoms. 
 
Nutrition was evaluated from three-day food records as in study I. Information 
about given therapies was collected from the patient charts.  
 
Laboratory investigations  
 
Laboratory investigations were similar to those in study I.  
 
 
The Ethics Committee of Helsinki University Hospital approved the study and the 








4.3 STUDY IV 
 
For the fourth study, interviews were pursued with Finnish-speaking adult patients 
with triad or oligosymtomatic forms of MRS or CG who had been treated and 
diagnosed with MRS in Helsinki University Hospital after the year 1995, and had 
participated in an MRS study in Helsinki University Hospital in 2007 [27]. The 
study cohort comprised 27 patients, 13 with triad or oligosymptomatic MRS and 




To evaluate the long-term outcome of patients with MRS, a phone interview was 
conducted with the patients. Patients were interviewed by an 
otorhinolaryngologist (AH) using a structural schema (appendix 4). The interview 
included a total of 42 questions regarding orofacial symptoms, facial palsy, 
intestinal symptoms, concomitant illnesses, medications, and possible food 
avoidances. In addition, family history of MRS, CG, and IBD was inquired. 
Additional information concerning the studied condition was collected from the 




To evaluate the possible inflammation in the gut, the subjects were asked to 
provide a stool sample for measuring faecal calprotectin in a routine clinical 
laboratory using a quantitative enzyme immunoassay (PhiCal Test, Calpro AS, 
Oslo, Norway). Values of <100 μg/g were considered to be normal [109,113]. Stool 
samples were collected from 18 subjects.  
 
 
The Ethics Committee of Helsinki University Hospital approved the study. All 
subjects signed an informed consent form.  
 
4.4 STATISTICAL ANALYSIS 
 
The nonparametric Mann-Whitney and Spearman correlation tests and the Fisher 
exact test were used to examine the associations between variables. In study II, 
Chi-square and Fisher exact test were applied, when appropriate. 
Statistical analyses were performed using GraphPad Prism 6 (study I) and 
GraphPad Prism 7 (study III-IV) for Windows (GraphPad Software Inc., San Diego, 




(analyses concerning nutrition in studies I and III. SPSS Inc., Chicago, IL). 





5.1 STUDY I 
 
In this study, patients diagnosed with pediatric OFG were clinically examined by 
an otorhinolaryngologist and a dentist. Study included questionnaires and 
evaluation of nutrition.  
 
Of the 29 patients, 21 (72%) had been diagnosed with CD during the time after the 
OFG diagnosis of median 3.1 years. Eleven patients had the OFG diagnosis before 
the CD diagnosis, and 5 patients got the diagnoses simultaneously (median time 
from OFG diagnosis to CD diagnosis 0.6 years, range 1 day – 4.6 years). Eight 
(28%) patients had not been diagnosed with CD. Patient characteristics are shown 
in Table 3.  
 
 
Table 3. Study I and II, Patient characteristics 
 





Age, median, years (range) 
At OFG diagnosis 12.3 (2.9-15.8) 
At Crohn´s disease diagnosis 12.3 (1.9-17.6) 
At study appointment 14.3 (6.8-31.1) 
Duration, years, median (range) 
Time after OFG diagnosis 3.1 (0.1-21.8) 
Diagnoses 
 OFG 29 
 Crohn’s disease 21 
 Previous surgery 3 
 Fistulazing perianal disease 7 





All except one of the 29 patients had oral findings at the time of the study. The 
activity of patients´ orofacial lesions according to total score of oral disease activity 
score chart for OFG ranged between 0 and 33 (median 10) out of a possible score 




scores higher compared to patients with OFG only (medians 11 and 7.5 
respectively, p=0.0351). The oral mucosa was the most common site of orofacial 
findings in 26 (90%) patients, following lesions in the lower lip (76%, mostly 
swelling), gingival lesions (66%) and angular cheilitis (48%) (Figure 1.). Pictures 
of typical findings are shown in Figure 2. Between patients with CD and patients 
with OFG only, there was a statistically significant difference only in the number 
of patients who had upper lip swelling (p=0.0265) which was more common in 
patients with CD (Table 4). The prevalence of cobblestoning, fibrous 
banding/scarring, facial swelling, facial erythema, and staghorning, did not differ 
significantly between patients with OFG and CD and patients with OFG only 
(Figure 3).  
 
Patients’ subjective evaluation regarding orofacial symptoms at study visit varied 
from 1 (no symptoms, n=11) to 6 (difficult symptoms, n=1), median 2 and in CD, 
regarding bowel-related symptoms between 1 (no symptoms, n=6) to 5 (rather 
difficult symptoms, n=2), median 2.5.   
 
Dental findings did not correlate statistically with the severity of the orofacial 
findings. All patients had gingivitis.  
 





Figure 1. Site of disease involvement in patients with OFG. Modified from the Journal 
of Pediatric Gastroenterology and Nutrition (Haaramo A et al: Detailed Follow-up 
Study of Pediatric Orofacial Granulomatosis Patients. J Pediatr Gastroenterol Nutr. 






Figure 2. Typical lesions in patients with OFG: Swelling of the lips (A, F), angular 







Figure 3. Inflammatory findings in patients with OFG only (OFG only) and in patients 


















Table 4. Site and type of disease involvement in patients with OFG and CD (OFG + CD) 
and patients with OFG only (OFG only). Modified from the Journal of Pediatric 
Gastroenterology and Nutrition (Haaramo A et al: Detailed Follow-up Study of 
Pediatric Orofacial Granulomatosis Patients. J Pediatr Gastroenterol Nutr. 2017; 
65(4): 388-393.)  
 all OFG + CD OFG only 
No. of patients 29 (%) 21 8 
Lips    
  Lower lip 22 (75.9)   
     swelling 19 15 4 
     erythema 7 5 2 
     ulcerations 1 1 0 
  Upper lip 11 (37.9)   
    swelling  10 10 0 
    erythema 3 3 0 
    ulcerations 3 3 0 
  Angular cheilitis 14 12 2 
Oral mucosa 26 (89.7)   
    swelling 13 11 2 
    erythema 5 4 1 
    tags 6 4 2 
    ulceration 3 3 0 
    fissures 7 6 1 
    nodules 13 8 5 
  Buccal sulcus 14   
    swelling 2 2 0 
    erythema 5 4 1 
    tags 5 4 1 
    ulceration 6 6 0 
    fissures 8 6 2 
Gingiva 19 (65.5)   
    swelling 10 8 2 
    erythema 16 13 3 
    ulcerations 0 0 0 
    nodules 4 4 0 
Tongue 5 (17.2)   
   swelling 0 0 0 
   erythema 2 2 0 
   ulcerations 2 2 0 
   fissures 1 1 0 
Floor of the mouth 4 (13.8)   
   swelling 0 0 0 
   erythema 1 1 0 
   tags 3 3 0 
Soft palate 5 (17.2)   
   swelling 2 0 2 
   erythema 1 0 1 
   nodules 3 3 0 
Hard palate 7 (24.1)   
   swelling 5 4 1 
   erythema 6 4 2 




Table 5. Otorhinolaryngological findings in patients with OFG and CD (OFG+CD) and 
patients with OFG (OFG only). Modified from the Journal of Pediatric 
Gastroenterology and Nutrition (Haaramo A et al: Detailed Follow-up Study of 
Pediatric Orofacial Granulomatosis Patients. J Pediatr Gastroenterol Nutr. 2017; 








 all OFG+CD OFG only  
No. of patients 29       21        8 
Lymph nodes  
    Enlargement of mental lymph nodes 1 0 1 
    Enlargement of submandibular lymph nodes 5 4 1 
    Enlargement of lateral cervical lymph nodes 1 1 0 
Salivary glands  
    Swelling of parotid glands 0   
    Swelling of submandibular glands 0   
Nose  
    Swelling of nasal conchae 0   
    Atrophy of nasal conchae 0   
    Erythema of nasal mucosa 6 4 2 
    Nasal polyps 0   
    Septum deviation 1 0 1 
    Septum perforation 0   
    Mucus in nasopharynx 2 1 1 
Pharynx  
    Undergone tonsillectomy 2 1 1 
    Tonsills    
        gradus I 17 12 5 
        gradus II 10 8 2 
        gradus III-IV 0   
    Chronic tonsillitis 0   
Larynx         26 
    Swelling of laryngeal cartilages 3 2 1 
    Erythema of laryngeal cartilages 3 2 1 
    Swelling of epiglottis 0   
    Erythema of epiglottis 1 1 0 
    Abnormal or dysfunctioning vocal cords 0   
Ears                                                                                       
    Swelling or secretion of ear canals 0   
    Abnormal tympanic membrane 0   
    Secretion in the middle ear 0   
    Tympanogram  27   
          A-curve 27 19 8 
          B-curve 0   






The most common treatment for OFG in this study´s cohort was topical tacrolimus 
gel in 15 patients (51.7%). Any topical treatment was received by 17 (59%) patients 
and none was was received by 12 (41%) patients (10 patients with CD and 2 with 
OFG only). One patient with OFG had received methotrexate, while others 
receiving systemic medication were patients with CD. At study point 3 (10%) 
patients were using topical tacrolimus, 4 (14%) azathioprine, 3 (10%) anti-TNF  




Elevated levels of CRP over 3 mg/L [114] were measured in six patients (median 
7.85, range 3.3-29.6 mg/L), all with CD. Elevated ESR was found in seven patients 
(median 25, range 13-38 mm/h), six with CD.  
 
Twelve patients had elevated levels of ASCAbG (median 32, range 26-95 IU/L). Of 
these, 10 had CD. Six patients had elevated ASCAbA levels (median 45, range 20-
167 IU/L) and were all diagnosed with CD. Interestingly, there was a significant 
relationship between elevated ASCAbA and patients´ total score of oral findings 
(p=0.0311) but no significant relationship between elevated ASCAbG and patients´ 
total score (p=0.0895). 
 
There was no significant relationship between patients´ faecal calprotectin levels 
and oral disease activity (Spearman´s r=0.03744, n=29, p=0.8471). As expected, 





Thirteen of the 28 patients that provided food records had eaten foods containing 
cinnamon. All except one patient had eaten food containing benzoic acid either in 
its natural forms or as an additive. Neither the consumption of cinnamon nor 
benzoic acid associated to orofacial findings (Spearman´s r=-0.2529, p=28, 
p=0.1942 and Spearman´s r=-0.06313, n=28, p=0.7496 respectively). 
 
Most variation was seen in the intake of dietary fiber, but no significant correlation 




Of the 29 patients with pediatric-onset OFG, 21 (72%) developed CD. Patients with 
OFG and CD had more oral findings than patients with OFG only. The oral mucosa 
was affected in 26 (90%) patients and was the most common site of orofacial 




patients with OFG only (p=0.0265), but other statistically significant differences 
in the orofacial findings between the groups were not found. Elevated levels of 
ASCAbA were found in patients with CD but not with OFG only. Patients with 
elevated levels of ASCAbA had also more oral findings compared to patients with 
normal levels of ASCAbA (p=0.0311).  
 
5.2 STUDY II 
 
In this study the HLA-haplotypes of patients with pediatric OFG were analysed to 
examine the relationship between HLA alleles and OFG. The results were 
compared between patients with OFG only and patients with OFG and CD. The 
groups were compared also to a cohort of pediatric patients with CD and to a 
general population cohort. 
 
The patients with OFG only and OFG with CD did not differ significantly in the 
HLA-allele or HLA-haplotype frequency. When comparing the HLA-allele 
frequencies between patients with OFG and CD, and the control cohort of patients 
with pediatric CD, HLA-B*44 was more common in patients with OFG and CD 
than in all pediatric CD patients (7/42, 16.67% and 7/122, 5.74% respectively, 
p=0.049). Compared with the general population, there was increased frequency 
of HLA-B*44 in patients with OFG and CD, but statistical significance was not 
reached (7/42, 16.7% in patients with OFG and CD vs. 25/300, 8.7%, in general 





One HLA-allele, namely HLA-B*44, was found to be associated with OFG, but not 
with CD.  
 
5.3 STUDY III 
 
This case-control study included clinical examination of adult patients with 
pediatric-onset CD. Evaluation of nutrition and health-related quality of life were 
included. Results were compared to matched healthy controls.  
 
The study group comprised 24 adult patients with pediatric-onset CD and 22 
healthy controls matched for age and sex. Patient characteristics are shown in 
Table 6. The median duration after the primary diagnosis of CD in the patients was 




Table 6. Study III, patient characteristics 
 
Number of subjects 46 
Patients with CD 
     Male 
24 (52.2%) 
14 (58.3%)  
     Previous surgery 5 (20.8%) 
     Fistulazing perianal disease 7 (29.2%) 
Healthy controls 22 (47.8%) 
     Male 11 (50.0%) 
Age in years, median (range) 
At Crohn´s disease diagnosis 13 (8-16) 
At study appointment  
        Patients with CD 22 (19-28) 
        Healthy controls 22 (19-29) 
Duration of CD in years, median (range) 





Of the 46 participants, 19 (41.3%) reported oral symptoms at some point of their 
life. Of the 24 patients with CD, 14 (58.3%) reported oral symptoms at some point 
during the course of the disease.  
 
At the time of the study, the patients and controls had very few oral findings and 
the total scores for OFG, according to the oral disease activity score chart, ranged 
between zero and three (median 0) out of a maximum score of 87. Of the 46 
subjects, 10 (21.7%) had findings in the orofacial area and these comprised eight 
(33.3%) of the 24 patients with CD and two (9.1%) of the 22 controls. All oral 
findings were recorded as mild. The most common oral finding was angular 
cheilitis in seven (15.2%) of the total of 46 subjects, including six with CD, but no 
statistical significance was reached between the controls and patients with CD 
(p=0.0984). None of the study subjects had cobblestoning, linear ulcers, fibrous 
banding/scarring, facial swelling, facial erythema, or staghorning. In addition, 
none of the patients had findings in their upper or lower lip, lower gingiva, tongue, 
floor of the mouth, hard palate, or pharynx. Four patients with CD who had oral 
findings at the time of the study had not reported any orofacial symptoms.  
 
Patients with CD and a history of perianal abscesses had more oral manifestations 
than patients without perianal disease (Spearman´s r=0.45, n=23, p=0.0312). No 
correlation was found between the time from the primary diagnosis of CD and 




The dental findings did not differ significantly between the patients with CD and 
controls. None of the dental findings correlated statistically significantly with the 
total score of oral manifestations. All except two subjects had gingivitis and only 
seven (15.2%) were cavity free with a DMTF score of zero.  
 
A comprehensive otorhinolaryngological examination was performed on all 
subjects but findings were very minor in both patients with CD and controls.  
 
Treatment for CD 
 
At the time of the study, 12 (50.0%) of the 24 patients with CD were treated with 
biological drug therapy and 17 (70.8%) had at some point of the disease course 
received biologicals. It did not have a significant effect on the oral findings wheter 
the patient received biologicals or not (Spearman´s r=0.01407, n=24, p=0.9480). 
Three patients had not received any medication for CD at the time of the study and 
there was no increase in their oral findings compared to the other patients with CD 
(p=0.9481).  
 
Health-related quality of life 
 
The mean HRQoL scores were lower in patients with CD, with a mean of 0.920 out 
of a possible score of one, compared with 0.951 for the controls. The difference was 
regarded as clinically important [112], but not statistically significant. There were 
slight differences between the groups in the dimensions of vision, breathing, 
sleeping, speech, excretion, usual activities, distress, depression, discomfort and 
symptoms, and vitality, as shown in Figure 4. However, the only statistically 
significant difference between the patients with CD and controls was found in the 
dimension of excretion (p≤0.01). When the subjects with oral findings, defined as 
a total OFG score of ≥1, were compared to those without oral findings, with a total 
OFG score of zero at the time of the study, subjects without oral findings fared 
better on every HRQoL dimension, except hearing, eating, and vitality. However, 
a statistically significant difference was found only in breathing (p<0.05), and 
subjects without oral findings had better scores. The disease duration in patients 







Figure 4. Health-related quality of life in patients with pediatric-onset CD studied at 
adult age and controls, as evaluated by the 15D questionnaire. Modified from the Journal 
of Clinical Gastroenterology (Haaramo A et al: Oral and otorhinolaryngological 
findings in adults who were diagnosed with pediatric-onset Crohn´s disease: a 
controlled study. J Clin Gastroenterol. 2018 Jun 16 doi: 






Twelve (26.1%) of the subjects had elevated CRP levels over 3 mg/L [114], but the 
patients with CD did not have higher CRP levels than the controls (Table 7). ESR 
was above the age related reference values [114] in seven (15.2%) of the 46 subjects, 
with a median of 5 mm/h (range 2-66 mm/h). ESR did not differ significantly 
between the patients with CD and controls and neither did the blood leukocyte 
(Table 7). 
 
Neither the CRP values nor the blood leukocyte counts correlated with the presence 
of orofacial symptoms, which would have been indicated by higher OFG total 
scores (Spearmans r=-0.01183, n=43, p=0.9378 and Spearman´s r=0.2133, n=43, 
p=0.1546 respectively). Instead, higher ESR failed to correlate with higher total 






Move=mobility, See=vision, Hear=hearing, Breath=breathing, Sleep=sleeping, Eat=eating, 
Speech=speech (communication), Excret=excretion, Uact=usual activities, Mental=mental 
































































Table 7. Laboratory test results in patients with Crohn´s disease (CD) and in controls 
 
Laboratory test 
Results, median (range) 
CD control  
CRP (mg/L) 1 (1-13) 1 (1-67) p=0.1639 















CRP=C-reactive protein, ESR=erythrocyte sedimentation rate. 
 
 
Seven (15.2%) of the 46 subjects had elevated levels of ASCAbA (median titre 30 
U/ml, range 23-156) and six of them had CD. Elevated levels of ASCAbG were 
found in six (13.0%) subjects (median 30 U/ml, range 27-63), including four who 
had CD. Elevated ASCAbA or ASCAbG levels failed to correlate significantly with 
the activity of subjects´ oral findings (Spearman´s r=-0.1012, n=46, p=0.5033 and 
Spearman´s r=0.07197, n=46, p=0.6346 respectively).  
 
Fourteen (32.6%) of the 43 subjects who provided a stool sample had elevated 
(≥100 μg/g) levels of faecal calprotectin (median 308, range 100-2488 μg/g). As 
expected, patients with CD had significantly higher calprotectin levels than the 
controls (p=0.002, Table 7), but these were not associated with more oral findings 
in patients with CD (Spearman´s r=0.1819, n=24, p=0.3948). One healthy control 
without gut symptoms had faecal calprotectin above the normal range (174 μg/g), 
but this was back to normal within in a couple of weeks, and further tests were 




Seventeen subjects (10 patients with CD (41.7%) and 7 controls (31.8%)) reported 
avoiding some food items in their diet. Avoiding lactose was most common (in 
seven subjects). Four patients (16.7%) and four controls (18.2%) reported food 
allergies.  
 
The consumption of benzoic acid and cinnamon were recorded from the food 
records. All but three of the 46 subjects had eaten food containing benzoic acid, 
either in its natural forms, or as an additive. No association was found between the 
amount of benzoic acid consumption and activity of oral findings (p=0.4127, 
Spearman´s r=-0.1643). In addition, the proportion of subjects who consumed 




(31.8%, p = 0.686) and there was no correlation between the amount of cinnamon 
consumption and activity of oral findings (p=0.1942, Spearman´s r=-0.2529). 
 
No difference in energy and nutrient intakes was seen between the patients and 
controls: the median intakes of carbohydrates, fiber and folic acid were lower than 
recommended in the patients and controls and the median intakes of saturated 
fatty acids were higher than recommended [115]. The oral findings did not 
correlate with energy intake (rs = 0.082, p=0.590), whereas those with moderate 
gastrointestinal symptoms received less energy than those with mild or no 
symptoms (22.9 vs 33.2 kcal/kg/day, p=0.042, t-test). However, there was no 
statistical difference in their body mass indexes, which were a median of 28.1 in 
the symptomatic subjects and a median of 23.6 in the subjects with mild or no 
symptoms (p= 0.150).  
 
Smoking and alcohol consumption 
 
Taking snuss (n=7) correlated with more orofacial findings and a higher total score 
(Spearman´s r=0.3343, n=46, p=0.0232), although the oral findings that were 
clearly caused by taking snuss, for example damage to the gingival mucosa in the 
exact place where the subject kept the snuss, were excluded from the total score 
count. However, smoking (n=3) did not correlate with more orofacial findings 
(Spearman´s r=-0.1472, n=46, p=0.3288). Alcohol consumption was modest in all 




Of the 24 patients with CD, 14 (58.3%) reported oral symptoms during the course 
of the disease. At the time of the study, both the patients and controls had very few 
oral findings, and the total scores for OFG ranged between zero and three (median 
0) out of a maximum score of 87. Statistically significant differencies in orofacial 
findings were not found between patients with CD and controls.  
Patients with CD and a history of perianal abscesses had more oral manifestations 
than patients without perianal disease (p=0.0312). 
The mean HRQoL scores were lower in patients with CD than in the controls. The 
only statistically significant difference between the patients with CD and controls 










5.4 STUDY IV 
 
In this follow-up study, patients with MRS were interviewed to evaluate the long-
term health outcomes of these patients. Faecal calprotectin was measured to 
investigate inflammation in the intestine. 
 
The study group comprised 27 patients. Triad or oligosymptomatic MRS was 
diagnosed in 13 (48.1%) patients and the monosymptomatic form of the syndrome, 
CG, in 14 (51.9%) patients. At initial presentation of symptoms of MRS or CG the 
patients were aged 10-71 years (median 24 years), resulting in a median of 29.7 
years follow-up. Patient characteristics are shown in Table 8.  
 
 
Table 8.  Study IV, patient characteristics 
 
Number of subjects 27 
Diagnoses 
Melkersson-Rosenthal syndrome 27 (100%) 
  Triad or oligosymptomatic form 13 (48.1%) 
      Female 7 (53.8%) 
      Male 6 (46.2%) 
  Monosymptomatic form (Cheilitis granulomatosa) 14 (51.9%) 
      Female 10 (71.4%) 
      Male 4 (28.6%) 
Age in years, median (range) 
At study appointment 57.8 (41.4-87.0) 
At diagnosis 38 (23-73) 
At presentation of symptoms 24 (10-71) 
  Duration in years, median (range) 
Follow-up after diagnosis  15.4 (10.9-34.9) 




Symptoms of MRS 
 
The prevalence of labial oedema, facial oedema, oedema elsewhere in the body and 
fissured tongue is listed in Table 9. During the course of the disease, 17 (63.0%) of 
the 27 patients had experienced swelling of the lips and 5 of them within the last 
year. Lip swelling was bilateral in 7 patients, while 5 patients reported swelling only 




recurrent, while in 5 patients it had occurred only once, and in 2 patients it had 
become persistant. Nine patients (33.3%) had experienced facial oedema other 
than lips at some point of the follow-up, and 6 of them within the last year, 2 within 
the last month. In all except one patient, facial oedema had occurred recurrently. 
The location of the facial swelling varied between the patients, but seemed to 
always occur in the same place in individual patients. The area around the mouth 
was the most common site, reported by 3 (11.1%) patients. Six (35.3%) patients 
reported oedema also in other body parts and the site varied in every patient.   
 
Of the 13 MRS patients with facial palsy, 9 (69.2%) had experienced recurrent 
episodes of facial palsy, while in four (30.8%) a palsy had occurred only once. In 6 
patients the facial palsy had manifested on both sides of the face during different 
episodes, while in 7 patients the palsy had affected only either the left or right side 
of the face. None of the patients with an original diagnosis of CG reported facial 
palsy.  
 
Of the 13 patients with MRS and facial palsy history, 9 (69.2%) had a fissured 




Of the 27 study participants, 15 (55.6%) reported some oral symptoms during the 
course of the disease. Aphtous ulceration or blistering was the most common 
complaint in the mouth in 9 (33.3%) patients. Actual ulcers in the mouth were 
reported in 3 patients. Erythema of the oral mucosa was reported by 3 patients and 
staghorning (extended nodules) by 2 patients. Angular cheilitis was experienced at 
some point of the disease course by 7 (25.9%) patients.  
 
Treatment for MRS and CG 
 
As a treatment for facial palsy, eight (61.5%) of the 13 MRS patients with facial 
palsy had received peroral cortisone at least once. Of the 14 patients with CG, six 
(42.9%) had received peroral cortisone for oedema. Cortisone injections, laser 
treatment, topical tacrolimuse (calcineurin inhibitor) and surgery were each 













Table 9. Symptoms in patients with triad or oligosymptomatic Melkersson-Rosenthal 
syndrome and cheilitis granulomatosa during the course of the disease (ever) and within 
the last year before the study interview (last year) as self-reported by the patients.  
 
Number of patients         27 
 ever last year 
Facial oedema 9 (33.3%) 6(22.2%) 
recurrent 8 (88.9%*) 6(66.7%*) 
nonrecurring 1 (11.1%*) 0 
bilateral  4 (44.4%*) 3(33.3%*) 
unilateral 5 (55.6%*) 3(33.3%*) 
location of facial oedema   
          nose and close to nose 2 (22.2%*) 2(22.2%*) 
          jaw  2 (22.2%*) 0 
          around the mouth  3 (33.3%*) 2(22.2%*) 
          neck, cheek, under the eyes 1 (11.1%*) 1(11.1%*) 
Labial oedema 17 (63.0%) 5 (18.5%) 
recurrent 10(58.9%**) 2(11.8%**) 
nonrecurring 5(29.4%**) 1(5.9%**) 
persistent 2 (11.8%**) 2(11.8%**) 
both lips 7 (41.2%**) 2(11.8%**) 
upper lip 5 (29.4%**) 1(5.9%**) 
lower lip 5 (29.4%**) 2(11.8%**) 
bilateral 12(70.6%**) 4(23.5%**) 
unilateral 5 (29.4%**) 1(5.9%**) 
Oedema elsewhere 6 (22.2%) 0 
Facial palsy 13 (48.1%) 1 (3.7%) 
     recurrent 9(69.2%***) 1(7.7%***) 
     nonrecurrent 4(30.8%***) 0 
Fissured tongue 11 (40.7%)  
*percentage of all facial oedema 
**percentage of all labial oedema 






Of the 27 patients, three (11.1%) were diagnosed with IBD; two MRS patients with 
UC, and one CG patient with CD. In addition, three patients were diagnosed with 
a functional condition, namely irritabile bowel syndrome. Six patients also had 
required clinical examination due to intestinal symptoms, but with negative 
results. None of the clinical features queried in the interview correlated 




with IBD, and was diagnosed with CD at the age of 27, after which she developed 
CG at the age of 35. Both patients with UC had MRS with facial palsy, which had 




Stool samples were collected from 18 patients to investigate the presence of 
intestinal inflammation using faecal calprotectin as a surrogate marker. Faecal 
calprotectin was above the normal level (>100μg/g) in 3 (16.7%) patients. Two of 
the patients with elevated levels of calprotectin had IBD. One non-IBD patient 
without intestinal symptoms had marginally elevated faecal calprotectin (144 




When queried about nutrition, 20 (74.1%) patients reported avoiding some food 
items in their diet. Eight (29.6%) patients reported avoiding certain food 
substances because they believed these substances were connected to oral or facial 
symptoms. Tomato, mustard, seasoning, ketchup, chocolate, kiwi, bell pepper, 
chili, food additives, and fruits and berries were mentioned to cause or exacerbate 
oedema in the lips (n=4), ulceration in the angle of the mouth (n=1) or aphtous 
ulceration in the mouth (n=2). One patient reported avoiding foods that contain 




Of the 27 patients, 15 (55.6%) reported oral symptoms at some point of the disease 
course. Eight (29.6%) patients reported avoiding food items due to causing oral or 
facial symptoms. Two MRS patients were diagnosed with UC and one CG patient 
was diagnosed with CD. Altogether 11.1% of the patients were diagnosed with IBD. 
Only one non-IBD patient had marginally elevated faecal calprotectin, other two 











6.1 OFG AND CD  
 
One of the main aims of this thesis was to investigate the connection between OFG 
and CD, and to evaluate the possible factors predicting the underlying or 
developing gut disease in patients with OFG. 
 
The largest study to date on OFG included 207 patients, who were traced 
retrospectively, including 22% of children [63]. The majority of the patients did 
not have CD nor develop it during the median of 5.5 years follow-up [63]. However, 
children who presented first with oral symptoms were more likely to develop CD 
than if the oral symptoms started in adulthood [63]. A review of 104 patients with 
pediatric OFG reported CD in about 40% of the patients, CD usually occurring 
before the onset of OFG [92]. In this study on patients with pediatric OFG, the 
frequency of CD was even higher, as the majority (72%) of the patients developed 
CD. In this study´s cohort, most patients presented first with OFG, and CD 
manifested later. Thus, it seems that pediatric-onset OFG may differ in clinical 
presentation from adult-onset disease. Childhood onset seems to carry a higher 
risk of developing CD in follow-up. High prevalence of CD in this study´s cohort 
may also be partly explained by patient selection. Patients were collected from two 
University Hospital units, where the most complicated cases are treated.  
 
Faecal calprotectin is acknowledged to be a noninvasive marker for intestinal 
inflammation [104,105]. It is used to estimate the activity of the gut disease in 
patients with IBD [102], and to identfy inflammation in the gut in patients with 
bowel symptoms. This study´s findings support the understanding that faecal 
calprotectin is useful also in identifying underlying gut disease in patients with 
OFG. Patients with CD had, as expected, significantly higher levels of faecal 
calprotectin than patients with OFG only.  
 
Concerning patients with MRS, this was the first study to systematically investigate 
the possibility of inflammation in the gut by measuring faecal calprotectin in these 
patients. Only one non-IBD patient with a marginally elevated value of faecal 
calprotectin was found. Several patients had experienced intestinal symptoms, but 
these patients did not have elevated levels of faecal calprotectin above 100μg/g, 
which would have indicated intestinal inflammation. Therefore, extensive 
screening for IBD in patients with MRS in the absence of gastrointestinal 
symptoms seems not beneficial, which is in line with earlier recommendations 
[91]. Nevertheless, it must be kept in mind that gastrointestinal inflammation is 
not completely ruled out when faecal calprotectin is between 50 and 99μg/g. In 




above 50 but under 100μg/g. Their calprotectin values were 55, 57 and 87μg/g, but 
only one of them reported intestinal symptoms. This patient group should be 
concidered for careful follow-up and controlling of faecal calprotectin if intestinal 
symptoms develop or proceed.  
 
Three (11.1%) of the 27 patients with MRS or CG were diagnosed with IBD, one 
patient (3.7%) with CD and two patients (7.4%) with UC. The reported prevalence 
of IBD in Finland was 595 per 100 ooo inhabitants in 2008 [13], and the current 
frequency of IBD in the Finnish population is 0.87% [116]. Thus, the prevalence of 
IBD was higher in this study´s cohort of patients with MRS or CG (11.1%) than in 
the general population, suggesting a link between MRS and IBD. A connection 
between MRS and CD has been described before, but a connection between MRS 
and UC is a novel finding, which has not been reported in the literature previously.   
 
In addition to faecal calprotectin, it has been suggested that it may be possible to 
use ASCAbA, a known serological marker for CD [97,98], as a marker of coincident 
gut disease in patients with OFG, and as a screening marker of the possible 
development of CD [50]. In this study on patients with pediatric OFG, patients with 
elevated ASCAbA were all diagnosed with CD. In addition, patients with elevated 
ASCAbA, but not those with elevated ASCAbG, had more orofacial findings than 
patients with normal ASCAbA levels. Thus, elevated ASCAbA levels might predict 
more severe oral disease and ASCAbA might arise as a serological marker to detect 
underlying or developing CD in patients with OFG. Further studies are needed to 
ensure the connection.  
 
Human leukocyte antigen (HLA) genes are associated with CD, although their 
overall effect on the pathogenesis of CD is not well established. HLA-B*44 is a class 
I HLA molecule that presents antigenic peptides to cytotoxic CD8+ T-cells [32]. 
The HLA-B*44 allele has previously been associated with type 2 polyarticular 
peripheral arthropathy in patients with IBD [117]. In this study, a possible 
connection between HLA-B*44 and OFG was found. Thus, HLA-B*44 may be a 
marker for OFG, and possibly a marker for extra-intestinal manifestations, 
including arthropathy and oral manifestations, in IBD. On the other hand, the 
finding that OFG with CD differed significantly from overall CD by having an 
increased frequency of HLA-B*44, suggests that OFG is not merely a manifestation 
of CD, but more likely a separate disease entity. Similar suggestion was made based 
on a small study from the UK, in which an association between OFG and HLA 
genotypes A3, B7 and DR2 was found [35]. The difference in their finding and this 
study´s finding rises the question of a possible geographical difference in the 
genetics of OFG.  
 
Exact diagnosing in the field of OFG is challenging. Different conditions and their 
subtypes, like OFG, MRS and CG as well as oral manifestations in CD, have similar 




not until after months or years of follow-up. This makes exact diagnosing difficult 
or even impossible, and inevitably leads to overlap in subgroups in studies. 
Therefore it may not be easy to find differences between subgroups. In addition, 
different studies are therefore not easily comparable. This may be one factor to 
explain the broad differences in incidences of many findings concerning these 
conditions reported in the literature. In this study, patients were collected from the 
same one or two tertiary care departments to minimize variation in classification 
and diagnostics, and thus to gain as comparable subgroups as possible.   
 
6.2 ORAL FINDINGS 
6.2.1 ORAL MANIFESTATIONS IN CD 
 
 
A prospective study of pediatric patients with suspected CD found oral pathology 
in approximately 40% of the patients, and these mostly went unnoticed before they 
were examined [118]. This led to the evaluation of the presence of oral 
manifestations in patients with pediatric CD when they reached adulthood. No 
detailed description of oral manifestations in pediatric-onset CD in adulthood has 
been published previously.  
 
More than half (58.3%) of the 24 patients with pediatric-onset CD in this study 
reported oral symptoms at some point in the course of the gut disease. At the time 
of the study, one third of the patients with CD had oral lesions. However, these 
were mostly isolated, and recorded as mild. The patients were receiving good 
therapeutic control for their gut disease during the study period, which may 
explain the reasonably low number of oral lesions. Thus, it seems that pediatric CD 
confers only a modest risk of oral lesions at adult age, although oral lesions were 
more common in the patients with CD than the controls, affecting one-third and 
one-tenth, respectively.  
 
A study by Laranjeira et al. with 113 adult patients with IBD – either UC or CD – 
and 58 controls, found that oral lesions increased over the course of the gut disease 
[119]. In this cohort, the length of follow up ranged from 4.7 to 15.2 years after the 
CD diagnosis, and the time period was not associated with oral findings. In the 
Laranjeira et al. study, patients in clinically active phases of IBD were the most 
affected [119], but in a study with child patients this kind of correlation was not 
found [17]. This study of patients with pediatric-onset CD who had reached 
adulthood showed no correlation between the oral findings and the subjective 
evaluation of the severity of current gut symptoms. In addition, there was no 
correlation between oral findings and levels of faecal calprotectin. Similarly, in 29 




association between faecal calprotectin and orofacial findings. This suggests that 
oral inflammation and intestinal inflammation are driven by different, but still 
uncharacterized, factors. In the future it would be interesting to examine the 
mouths of patients with CD during the active phases of the gut disease.  
 
A specific risk factor for oral findings in CD in adulthood was a history of perianal 
abscesses, which is an indicator of a complicated disease subtype of CD [120]. 
Others have also reported such an association between perianal CD and oral 
findings [17,23,118,121,122]. In children it has been suggested that the presence of 
oral manifestations, especially at the presentation of the gut disease, but 
presumably not later during the course of the disease, might be a marker for a 
severe CD subtype [17]. Therefore, it may be beneficial for the clinician to look in 
the mouths of patients with CD to find clues of a possible severe disease subtype. 
The oral cavity is easily accessible and can help clinicians to detect those patients 
who are in need of more accurate follow-up of the gut disease. Further studies with 
preferably larger cohorts are needed to ensure the true possibilities of the 
examination of the oral cavity in terms of assessing the circumstances in the gut.    
6.2.2 CLINICAL PRESENTATION OF ORAL FINDINGS IN CD AND OFG 
 
The spectrum of oral lesions reported in patients with CD varies widely. 
Cobblestoning, followed by linear ulcers have been reported to be the most 
common oral lesions in patients with CD [20]. The lips [21] and the labial 
commissure [22] have been reported to be the most frequently affected sites. In 
reviews on pediatric patients with CD, mucogingivitis [17] and oral ulceration [18] 
were the most common oral lesions. In this cohort of adult patients with pediatric-
onset CD, angular cheilitis was the most frequently seen oral manifestation, while 
all other lesions were sporadic. Angular cheilitis was also common in patients with 
OFG, and was found in almost half of the patients. In patients with MRS, angular 
cheilitis was reported in a quarter of the patients. However, angular cheilitis is not 
specific to OFG or CD and it is seen quite commonly in otherwise healthy 
individuals. In patients with OFG, the most common findings according to the 
literature are lip swelling and facial swelling, reported in more than 90% of cases 
[64,66]. In this study the most common individual finding was swelling of the 
lower lip, which was present in about 65% of the patients with OFG. However, the 
most common site for orofacial lesions was the buccal mucosa, where almost 90% 
of the patients had some findings. The only statistically significant difference 
between patients with OFG and CD and patients with OFG only was the more 
frequent swelling of the upper lip in patients with concurrent CD. Concerning all 
other orofacial findings, no statistically significant differences between these 





Patients with OFG had plenty of oral findings at the time of the study, but stated 
that they were mostly asymptomatic. Altogether, evaluation of patients with 
pediatric-onset OFG after 3.1 years (median) after diagnosis, showed good 
prognosis and severe disease exacerbations were not detected. Interestingly, 
patients with OFG who had CD had more oral findings compared to patients with 
OFG only.  
 
Over half of the patients with MRS reported lesions in the mouth at some point of 
their disease, the proportion being similar to patients with pediatric-onset CD in 
adulthood. Aphtous ulceration and blistering were the most common lesions in the 
mouth in patients with MRS. Some of the patients reported that symptoms in the 
mouth coincide with the facial oedema, while others had not noticed a time 
connection between the oedema and ulceration in the mouth. Interestingly, over 
half of the patients who reported oral lesions, had noticed that certain food 
substances cause or exacerbate the symptoms and therefore avoided those 
substances in their diet. Allergens in food seem to have a role in oral and labial 
symptoms of MRS as self-reported by the patients, but further studies on this topic 
are needed. 
 
Biopsy and histopathological examination are not mandatory in the diagnosis of 
OFG, which is based on the typical clinical presentation of oral manifestations. 
Similarly, in MRS the diagnosis is clinical and biopsy is not necessary although the 
granulomatous changes would confirm the diagnosis. However, a biopsy is needed 
in certain cases if the possibility of a malignancy as a diagnostic option emerges. 
The possibility of a malignancy must be kept in mind if an oral lesion is not typical 
or does not respond well to treatment. In such cases, a biopsy is naturally 
mandatory and of great value.  
 
6.3 OTORHINOLARYNGOLOGICAL FINDINGS 
 
Otorhinolaryngological findings in patients with OFG or CD have not been 
reported in detail before. Surprisingly the otorhinolaryngological findings of 
patients were minor in these cohorts, both in patients with pediatric-onset OFG 
and in adult patients with pediatric-onset CD. Most subjects had normal findings 
in comprehensive otorhinolaryngological examination, which included 
fiberoscopy of the nasopharynx and larynx. This strengthens the assumption that 
OFG is restricted in the oral cavity and area around the mouth and does not affect 
the nasal mucosa, nor the larynx or the ears. In patients with CD signs of acute or 
chronic inflammation were not detected, which goes together with the assumption 
that inflammatory changes in CD are restricted to the gastrointestinal tract without 
excess otorhinolaryngological comorbidity. Based on clinical experience, patients 




patients´ own evaluation of nasal obstruction, nor the clinical findings of the nasal 
cavity and nasal conchae, differed significantly between the patients with CD and 
controls. In addition, nasal obstruction causing nasal polyps were not detected. A 
detectable adenoid was as common in the CD group as in the controls, but 
interestingly all patients with a mucous adenoid had CD.  
 
The involvement of salivary glands in OFG has been suggested based on the finding 
that non-specific immunoglobulin levels in both whole saliva and parotid saliva 
were raised in patients with OFG with or without gut inflammation [50]. In this 
study, the clinical examination (palpation) of salivary glands was normal 
suggesting that salivary glands were unaffected. Subclinical involvement is 
naturally not precluded. However, if OFG patient´s salivary glands are affected, 
sarcoidosis should be considered in differential diagnosing as an uncommon cause 
of orofacial lesions, similar to OFG [123]. Inflammation in the oral cavity would be 
expected to result in enlargement of the cervical lymph nodes, but this was seen 
only in few patients in this study, although oral findings were seen in most of the 
patients with OFG.  
 
Patients with OFG can primarily present to an otorhinolaryngologist with their 
various orofacial symptoms and otorhinolaryngologists should be familiar with 
this entity and remember the possibility of an underlying gut disease.  
 
6.4 STRENGTHS AND LIMITATIONS 
 
A valid strength of this series of studies is comprehensiveness. The studies include 
otorhinolaryngological examination, dental examination, nutritional aspects, 
laboratory tests, and evaluation of health-related quality of life. Orofacial 
manifestations are evaluated from many different aspects.  
 
Otorhinolaryngological findings of patients with OFG and patients with pediatric-
onset CD in adulthood have not been published before. It was surprising that there 
were so few otorhinolaryngological findings.  
 
Nutrition was evaluated from three-days food records. Keeping a food diary 
requires writing down precisely everything that is eaten. This can be challenging 
for anybody and it contains a risk for errors. Underreporting is an acknowledged 
finding in the food records [124]. In children, the guardian made the markings to 
the food diary, but it is likely that the guardian was not present in every eating 
situation if the patient was in school or in daycare, which increases the risk for 
errors. To minimize the errors, a trained nurse checked the food records upon 
returning for possible omissions and controversies. Use of an electronic food diary 




alerts for obscurity, may decrease the possibility for omissions in food records in 
the future.  
In study IV, a phone interview was performed. The symptoms were therefore self-
reported by the patients which includes the possibility of recall bias. Patients´ 
experience in recognizing and evaluating the symptoms may vary between 
individuals, and it can affect reporting. However, performing the study as a phone 
interview presumably increased the number of participants. In addition, the 
advantages of the phone-interview were that defining questions could be asked of 
the patients if needed, and long-distance patients and patients from older age 
groups, who may find filling questionnaires or attending study visits difficult, could 
be reached. A proper clinical examination of the symptoms is difficult to arrange 
due to long symptom-free intervals in MRS.  
 
In study IV, the long follow-up time after both presentation of symptoms and 
diagnosis is a valid strength. This is the longest follow-up of patients with MRS 
published to date. In addition, evaluating the possibility of underlying 
inflammation in the gut using faecal calprotectin as a surrogate marker has not 
been systematically done in patients with MRS before.  
 
The relatively small number of patients is a limitation in the studies. In study III, 
recruiting young adults to the study turned out to be more challenging than 
expected. In study IV however, considering the rare nature of MRS and the long 
follow-up time, the number of patients included in the study was fairly good.  
 
6.5 FUTURE PROSPECTIVES 
 
The role of gut microbiota in immunity-related disorders is increasingly 
recognized. The strong modification of gut microbiota composition is the most 
important environmental factor associated with the development of CD [8]. 
Examining the composition of gut microbiota in patients with OFG is of particular 
interest for future research, and would likely provide new insights to etiology and 
treatment. Comparing the microbiota of patients with orofacial disease and those 
with CD, as well as patients with MRS, would advance knowledge of the 
relationships between these conditions. In addition to gut microbiome, the role of 
oral microbiome is of high interest. The oral microbiome is a direct precursor of 
oral conditions such as dental caries and periodontitis [125]. The influence of 
oral microbiome can extend beyond the oral cavity and systemic conditions such 
as coronary artery disease and rheumatoid arthritis are associated with oral 
microbiome [126,127]. The role of oral microbiome in the development of OFG 
and CD is also an interesting issue for future research [128].  
 
To draw more precise conclusions of the clinical use of ASCAbA as a factor 




thesis should be tested in preferably larger patient cohorts. In addition, the true 







OFG remains a rare entity. The study shows that prognosis for OFG is good. 
Symptoms tend to diminish during the course of the disease and topical treatment 
seems to be efficient and safe. When accompanied by CD, the oral symptoms seem 
to be inactive when the gut disease is under good therapeutic control. Pediatric CD 
confers only a modest risk of oral lesions at adult age.   
 
In addition to faecal calrotectin, elevated serum ASCAbA may serve as a factor 
predicting the underlying or developing CD in patients with OFG, but further 
studies are warranted. 
 
Tissue antigen HLA-B*44 might be a marker for OFG. On the other hand, patients 
with CD and a history of perianal abscessing disease seem to be prone to develop 
oral manifestations of CD. In addition, elevated ASCAbA also connects to more 
severe oral manifestations in patients with OFG with or without CD, but further 
studies are needed to ensure the connection.  
 
OFG or CD does not seem to increase otorhinolaryngological comorbidity.  
 
Oral manifestations in MRS do not seem to increase during the course of the 
disease, although over half of the patients reported oral symptoms at some point 
of the disease. Incidence of IBD was higher among the patients with MRS than 
reported in the Finnish general population. This suggests a link between MRS and 
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Type of lesion legend
Upper lip (1) 
      
1 Oedema 
Lower lip (1) 
      
2 Tags 
Angular cheilitis (1) 
      
3 Ulceration 
Buccal mucosa left (<50% = 1, >50% = 2)
      
4 Linear ulcers 
Buccal mucosa right oikea (1 or 2) 
      
5 Erythema 
Buccal sulcus left (1 or 2) 
      
6 Fissures 
Buccal sulcus right (1 or 2) 
      
7 Nodules 
Gingiva (1 each segment) 
          
  Lower right (distal) 
          
  Lower central  
          
  Lower left (distal) 
      
Activity legend
  Upper right (distal) 
      
0 Absent 
  Upper central 
      
1 Mild 
  Upper left (distal) 
      
2 Moderate 
Dorsum of the tongue (1 or 2) 
      
3 Severe 
  Lateral tongue right (1) 
          
  Lateral tongue left (1) 
          
Floor of the mouth (1 or 2) 
          
Hard palate (1 or 2) 
          
Soft palate (1 or 2) 
          
Pharynx (1 or 2) 
          
TOTAL










APPENDIX 2. SCHEMA FOR OTORHINOLARYNGOLOGICAL EXAMINATION 
 
Inspection of the face                
                                                 oedema                       erythema                  
around the mouth                   yes          no                yes            no                
cheeks                                        yes          no                yes            no 
comments: 
 
Palpation of the neck                                                     
                                                                                   right                                                         left 
enlarged lymph nodes                               
   mental region                                                          yes           no                                        yes         no 
   submandibular region                                            yes           no                                        yes         no 
   lateral cervical region                                             yes           no                                        yes         no 
 
Salivary glands                                             
                                                                                    right                                                     left 
Parotid glands 
     oedema                                                                     yes          no                                           yes         no 
     pain                                                                         yes           no                                           yes         no 
Submandibular glands 
     oedema                                                                    yes          no                                            yes         no 
     pain                                                                         yes          no                                            yes         no 
 
Anterior rhinoscopy                                            
                                                                                    right                                                      left 
conchae                                                                   
   oedema                                                                       yes         no                                          yes          no 
   atrophy                                                                     yes         no                                          yes           no 
mucosa 
   pale                                                                          yes          no                                            yes        no 
   redness                                                                    yes          no                                           yes         no 
   polyps                                                                      yes          no                                           yes         no 
septum                             
   deviation                                                                   yes        no                                              
   septum perforation                                                 yes        no               
                     
Pharynx                                                                                                                             
tonsils                        gradus I                gradus II           gradus III                     
    tonsilloliths            yes          no 













                                                                    right                                                    left 
vocal cords                                                                                                                     
    erythema                                                yes             no                                  yes            no 
    oedema                                                     yes             no                                  yes            no 
     
    movement                                               yes           no                                  yes            no     
    normal                                                     yes            no                                  yes            no 
arythenoids                                                     
    oedema                                                     yes             no                                  yes            no 
    erythema                                                yes             no                                  yes            no 
     
    normal                                                    yes              no                                  yes           no 
epiglottis     
     oedema                   yes              no 
     erythema              yes              no 
 
Ears                                                                         
                                                                    right                                                     left 
Ear canal 
    secretion                                                  yes           no                                      yes           no 
    oedema                                                      yes           no                                      yes           no 
    erythema                                                 yes           no                                      yes           no 
Tympanic membrane 
     normal                                                    yes            no                                      yes           no 
     perforation                                             yes            no                                      yes          no   
 Middle ear 
     secretion                                                  yes          no                                      yes           no   
     comments: 
 
Tympanometer                                               
                                                                        right                                                    left 
     A-curve 
     B-curve 
     C-curve 
not done   
 
Tuning fork tests 
Rinne (+/-)      right                   left 
Weber                     middle 
                                 right 







APPENDIX 3. THE 15-DIMENSIONAL MEASURE OF HEALTH-RELATED 
QUALITY OF LIFE (15D) 
 
Please read through all the alternative responses to each question before placing a cross 
(x) against the alternative which best describes your present health status. Continue 
through all 15 questions in this manner, giving only one answer to each. 
 
QUESTION 1. MOBILITY 
1 ( ) I am able to walk normally (without difficulty) indoors, outdoors and on stairs. 
2 ( ) I am able to walk without difficulty indoors, but outdoors and/or on stairs I have slight 
difficulties. 
3 ( ) I am able to walk without help indoors (with or without an appliance), but outdoors 
and/or on stairs only with considerable difficulty or with help from others. 
4 ( ) I am able to walk indoors only with help from others. 
5 ( ) I am completely bed-ridden and unable to move about. 
 
QUESTION 2. VISION 
1 ( ) I see normally, i.e. I can read newspapers and TV text without difficulty (with or 
without glasses). 
2 ( ) I can read papers and/or TV text with slight difficulty (with or without glasses). 
3 ( ) I can read papers and/or TV text with considerable difficulty (with or without glasses). 
4 ( ) I cannot read papers or TV text either with glasses or without, but I can see enough to walk 
about without guidance. 
5 ( ) I cannot see enough to walk about without a guide, i.e. I am almost or completely blind. 
 
QUESTION 3. HEARING 
1 ( ) I can hear normally, i.e. normal speech (with or without a hearing aid). 
2 ( ) I hear normal speech with a little difficulty. 
3 ( ) I hear normal speech with considerable difficulty; in conversation I need voices to be louder 
than normal. 
4 ( ) I hear even loud voices poorly; I am almost deaf. 
5 ( ) I am completely deaf. 
 
QUESTION 4. BREATHING 
1 ( ) I am able to breathe normally, i.e. with no shortness of breath or other breathing difficulty. 
2 ( ) I have shortness of breath during heavy work or sports, or when walking briskly on flat 
ground or slightly uphill. 
3 ( ) I have shortness of breath when walking on flat ground at the same speed as others my age. 
4 ( ) I get shortness of breath even after light activity, e.g. washing or dressing myself. 
5 ( ) I have breathing difficulties almost all the time, even when resting. 
 
QUESTION 5. SLEEPING 
1 ( ) I am able to sleep normally, i.e. I have no problems with sleeping. 
2 ( ) I have slight problems with sleeping, e.g. difficulty in falling asleep, or sometimes 
waking at night. 
3 ( ) I have moderate problems with sleeping, e.g. disturbed sleep, or feeling I have not slept 
enough. 
4 ( ) I have great problems with sleeping, e.g. having to use sleeping pills often or routinely,or 
usually waking at night and/or too early in the morning. 
5 ( ) I suffer severe sleeplessness, e.g. sleep is almost impossible even with full use of 





QUESTION 6. EATING 
1 ( ) I am able to eat normally, i.e. with no help from others. 
2 ( ) I am able to eat by myself with minor difficulty (e.g. slowly, clumsily, shakily, or with 
special appliances). 
3 ( ) I need some help from another person in eating. 
4 ( ) I am unable to eat by myself at all, so I must be fed by another person. 
5 ( ) I am unable to eat at all, so I am fed either by tube or intravenously. 
 
QUESTION 7. SPEECH 
1 ( ) I am able to speak normally, i.e. clearly, audibly and fluently. 
2 ( ) I have slight speech difficulties, e.g. occasional fumbling for words, mumbling, or 
changes of pitch. 
3 ( ) I can make myself understood, but my speech is e.g. disjointed, faltering, stuttering or 
stammering. 
4 ( ) Most people have great difficulty understanding my speech. 
5 ( ) I can only make myself understood by gestures. 
 
QUESTION 8. EXCRETION 
1 ( ) My bladder and bowel work normally and without problems. 
2 ( ) I have slight problems with my bladder and/or bowel function, e.g. difficulties with 
urination, or loose or hard bowels. 
3 ( ) I have marked problems with my bladder and/or bowel function, e.g. occasional 
'accidents', or severe constipation or diarrhea. 
4 ( ) I have serious problems with my bladder and/or bowel function, e.g. routine 'accidents', 
or need of catheterization or enemas. 
5 ( ) I have no control over my bladder and/or bowel function. 
 
QUESTION 9. USUAL ACTIVITIES 
1 ( ) I am able to perform my usual activities (e.g. employment, studying, housework, freetime 
activities) without difficulty. 
2 ( ) I am able to perform my usual activities slightly less effectively or with minor difficulty. 
3 ( ) I am able to perform my usual activities much less effectively, with considerable 
difficulty, or not completely. 
4 ( ) I can only manage a small proportion of my previously usual activities. 
5 ( ) I am unable to manage any of my previously usual activities. 
 
QUESTION 10. MENTAL FUNCTION 
1 ( ) I am able to think clearly and logically, and my memory functions well 
2 ( ) I have slight difficulties in thinking clearly and logically, or my memory sometimes fails me. 
3 ( ) I have marked difficulties in thinking clearly and logically, or my memory is somewhat 
impaired. 
4 ( ) I have great difficulties in thinking clearly and logically, or my memory is seriously 
impaired. 
5 ( ) I am permanently confused and disoriented in place and time. 
 
QUESTION 11. DISCOMFORT AND SYMPTOMS 
1 ( ) I have no physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc. 
2 ( ) I have mild physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc. 
3 ( ) I have marked physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc. 
4 ( ) I have severe physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc. 





QUESTION 12. DEPRESSION 
1 ( ) I do not feel at all sad, melancholic or depressed. 
2 ( ) I feel slightly sad, melancholic or depressed. 
3 ( ) I feel moderately sad, melancholic or depressed. 
4 ( ) I feel very sad, melancholic or depressed. 
5 ( ) I feel extremely sad, melancholic or depressed. 
 
QUESTION 13. DISTRESS 
1 ( ) I do not feel at all anxious, stressed or nervous. 
2 ( ) I feel slightly anxious, stressed or nervous. 
3 ( ) I feel moderately anxious, stressed or nervous. 
4 ( ) I feel very anxious, stressed or nervous. 
5 ( ) I feel extremely anxious, stressed or nervous. 
 
QUESTION 14. VITALITY 
1 ( ) I feel healthy and energetic. 
2 ( ) I feel slightly weary, tired or feeble. 
3 ( ) I feel moderately weary, tired or feeble. 
4 ( ) I feel very weary, tired or feeble, almost exhausted. 
5 ( ) I feel extremely weary, tired or feeble, totally exhausted. 
 
QUESTION 15. SEXUAL ACTIVITY 
1 ( ) My state of health has no adverse effect on my sexual activity. 
2 ( ) My state of health has a slight effect on my sexual activity. 
3 ( ) My state of health has a considerable effect on my sexual activity. 
4 ( ) My state of health makes sexual activity almost impossible. 







APPENDIX 4. PHONE INTERVIEW QUESTIONNAIRE, STUDY IV 
 
 
The patient is diagnosed with  1) MRS  2) CG 
 
FACIAL SYMPTOMS 
Have you experienced facial edema? 1) yes 2) no 
 -during the last year 1) yes  2) no 
 -during the last month 1) yes 2) no 
 -which part of the face is affected? 
 -which side of the face is affected: 1) right 2) left 3) both 
 -is the symptom 1) recurrent 2) persistent 
Have you experienced labial edema?  1) yes 2) no 
-during the last yea 1) yes 2) no 
 -during the last month 1) yes 2) no 
 -if yes:  1) upper lip 2) lower lip 
 -which side: 1)right 2) left 3) both 
 -is the symptom 1) recurrent 2) persistent 
Have you experienced edema elsewhere in the body? 1) yes 2) no  
 -if yes, where? 
Have you experienced lesions in the mouth? 1) yes 2) no 
 -during the last year 1) yes 2) no 
 -during the last month 1) yes 2) no 
 -comments: type, location, pain, recurrency, etc 
Have you experienced angular cheilitis/ ulceration in the corner of the mouth? 1) yes 2)no 
 -during the last year 1) yes 2) no 
 -during the last month 1) yes 2) no 
Have you experienced facial palsy? 1) yes 2)no 
 -if yes: 1 ) recurrently 2) once 
 - which side: 1)right 2) left 3) both  




 -during the last month 1) yes 2) no  
 - comments: note the side of the palsy at different episodes 
In MRS patients, treatment?  
 




Do you have a diagnosed intestinal disease?  
1) Crohn´s disease 2) ulcerative colitis 3) coeliac disease 4) other ____________ 5) 
no 
Have you experienced intestinal symptoms that have required medical examination? 1) yes 2) 
no 
 -comments: type, intensity, etc 
Have you experienced diarrhea during the last month? 1) yes 2) no 




d. 9 or more 
Have you experienced abdominal pain during the last month?  
a. Yes, almost daily 
b. Yes, every now and then 
c. Not at all 
Have you had to excrete during the night during the last month? 
a. no 
b. yes, 1-2 nights a week 
c. yes, 3-4 nights a week  
d. yes, 5-6 nights a week  
e. yes, every night 
Have you had blood in the feces during the last month? 




b. Yes, occasionally  
c. Not at all 
d. I don´t know (I never look) 
Do you avoid some food items in your diet? 1) yes 2) no      
                   -if yes, which and why? 
 
OTHER 
Have you been diagnosed with a chronic condition?  
 Asthma 1) yes 2) no 
 Cardiovascular disease 1) yes 2) no     If yes, which? 
 Kidney disease 1) yes 2) no     If yes, which? 
 Other, which?  
Do you have regular medications 1) yes 2) no     If yes, which? 
Do you have a close relative with  
 Melkersson-Rosenthal syndrome 1) yes 2) no     If yes, relationship? 
 Cheilitis granulomatosa 1) yes 2) no     If yes, relationship? 
 Crohn´s disease 1) yes 2) no     If yes, relationship? 
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